TRILOGY ACS: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
Sponsor
Eli Lilly and Company (Industry)
Overall Status
Completed
CT.gov ID
NCT00699998
Collaborator
Daiichi Sankyo Co., Ltd. (Industry), Duke Clinical Research Institute (Other)
9,326
688
2
46
13.6
0.3
Study Details
Study Description
Brief Summary
This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is, patients who are not managed with acute coronary revascularization).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Based upon the significant number of subjects with UA/NSTEMI ACS who are managed medically and their high risk for future cardiovascular events, further exploration of novel treatment strategies for this population, who are under-represented in large clinical trials, is warranted. Potential subjects will be those with a recent UA/NSTEMI event who are to be medically managed. Eligibility for this study will be determined by both the timing of the medical management decision and by prior commercial clopidogrel treatment at the time of randomization. The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) Study will assess the efficacy and safety of prasugrel and aspirin compared to the current standard of care, clopidogrel and aspirin, for long-term treatment of medically managed UA/NSTEMI ACS subjects.
Study Design
Study Type:
Interventional
Actual Enrollment
:
9326 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed
Study Start Date
:
Jun 1, 2008
Actual Primary Completion Date
:
Apr 1, 2012
Actual Study Completion Date
:
Apr 1, 2012
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Prasugrel Prasugrel and Low-dose Commercially-available Aspirin |
Drug: Prasugrel
30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
Other Names:
Drug: Commercially-available Aspirin
Low-dose aspirin, oral, as prescribed by physician through end of study
|
| Active Comparator: Clopidogrel Clopidogrel and Low-Dose Commercially-available Aspirin |
Drug: Clopidogrel
300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
Drug: Commercially-available Aspirin
Low-dose aspirin, oral, as prescribed by physician through end of study
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke [Randomization through end of study (30-month visit)]
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.
Secondary Outcome Measures
- Percentage of Participants With a Composite Endpoint of CV Death and MI [Randomization through end of study (30-month visit)]
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee.
- Percentage of Participants With a Composite Endpoint of CV Death, MI, Stroke, or Re-hospitalization for Recurrent Unstable Angina (UA) [Randomization through end of study (30-month visit)]
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee.
- Percentage of Participants With a Composite Endpoint of All-cause Death, MI, or Stroke [Randomization through end of study (30-month visit)]
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee.
- Platelet Aggregation Measures [Day 30 and 12 Months]
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization.
- Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP) [Day 30 and 6 Months]
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization.
- Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP) [Day 30 and Month 6]
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization.
- Genotyping Related to Drug Metabolism [Baseline]
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100.
- Economic and Quality of Life Outcomes [Baseline and follow-up (24 months)]
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life.
- Summary of All Deaths [Randomization through end of study (30-month visit)]
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module.
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Key Inclusion Criteria:
-
Have had a Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) index event within 10 days prior to randomization
-
Had a medical management strategy decision made with reasonable certainty that neither percutaneous coronary intervention (PCI) nor coronary artery bypass graft (CABG) is planned for treatment of the index event
-
Had at least 1 of 4 specified high-risk features at the time of the UA/NSTEMI event
Key Exclusion Criteria:
-
Decision for medical management greater than 72 hours after onset of index event without commercial clopidogrel treatment within 72 hours following onset of the index event.
-
Insignificant coronary artery disease (CAD) on coronary angiography if performed for Index Event (absence of greater than or equal to 30% stenosis in at least one native vessel)
-
Previous or planned PCI or CABG as treatment for the index event
-
PCI/CABG within previous 30 days
-
ST-segment elevation myocardial infarction (STEMI) as the index event
-
Cardiogenic shock, Refractory ventricular arrhythmias, New York Heart Association (NYHA) Class IV congestive heart failure (CHF) within the previous 24 hours
-
History of ischemic or hemorrhagic stroke, transient ischemic attack (TIA), Intracranial neoplasm, arteriovenous malformation, or aneurysm
-
History of spontaneous gastrointestinal (GI) or non-GI bleeding requiring hospitalization for treatment, unless definitive treatment has occurred and there is low likelihood of recurrence
-
Hemodialysis or peritoneal dialysis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Birmingham | Alabama | United States | 35233 |
| 2 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Huntsville | Alabama | United States | 35801 |
| 3 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Glendale | Arizona | United States | 85306 |
| 4 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tucson | Arizona | United States | 85724 |
| 5 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Fort Smith | Arkansas | United States | 72917 |
| 6 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Anaheim | California | United States | 92801 |
| 7 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Banning | California | United States | 92220 |
| 8 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bellflower | California | United States | 90706 |
| 9 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Healdsburg | California | United States | 95448 |
| 10 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lancaster | California | United States | 93534 |
| 11 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Long Beach | California | United States | 90822 |
| 12 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Los Angeles | California | United States | 90027 |
| 13 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mather | California | United States | 95655 |
| 14 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Newport Beach | California | United States | 92663 |
| 15 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Palo Alto | California | United States | 94304 |
| 16 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sacramento | California | United States | 95817 |
| 17 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Diego | California | United States | 92123 |
| 18 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sylmar | California | United States | 91342 |
| 19 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Yuba City | California | United States | 95991 |
| 20 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Colorado Springs | Colorado | United States | 80909 |
| 21 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Denver | Colorado | United States | 80218 |
| 22 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Loveland | Colorado | United States | 80538 |
| 23 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wheat Ridge | Colorado | United States | 80033 |
| 24 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Washington | District of Columbia | United States | 20422 |
| 25 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Atlantis | Florida | United States | 33462 |
| 26 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Aventura | Florida | United States | 33180 |
| 27 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Boynton Beach | Florida | United States | 33472 |
| 28 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Brandon | Florida | United States | 33511 |
| 29 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Deerfield Beach | Florida | United States | 33442 |
| 30 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hudson | Florida | United States | 34667 |
| 31 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lakeland | Florida | United States | 33805 |
| 32 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Melbourne | Florida | United States | 32901 |
| 33 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Miami | Florida | United States | 33176 |
| 34 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Orlando | Florida | United States | 32803 |
| 35 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ormond Beach | Florida | United States | 32174 |
| 36 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Panama City | Florida | United States | 32401 |
| 37 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pensacola | Florida | United States | 32501 |
| 38 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Port Charlotte | Florida | United States | 33952 |
| 39 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sarasota | Florida | United States | 34232 |
| 40 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tallahassee | Florida | United States | 32308 |
| 41 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tampa | Florida | United States | 33613 |
| 42 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Trinity | Florida | United States | 34655 |
| 43 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | West Palm Beach | Florida | United States | 33401 |
| 44 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Atlanta | Georgia | United States | 30342 |
| 45 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Covington | Georgia | United States | 30014 |
| 46 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Decatur | Georgia | United States | 30033 |
| 47 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Riverdale | Georgia | United States | 30274 |
| 48 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Savannah | Georgia | United States | 31405 |
| 49 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Melrose Park | Illinois | United States | 60160 |
| 50 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Peoria | Illinois | United States | 61614 |
| 51 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rock Island | Illinois | United States | 61201 |
| 52 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Anderson | Indiana | United States | 46011 |
| 53 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Elkhart | Indiana | United States | 46514 |
| 54 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hammond | Indiana | United States | 46320 |
| 55 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Indianapolis | Indiana | United States | 46250 |
| 56 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Muncie | Indiana | United States | 47303 |
| 57 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Valparaiso | Indiana | United States | 46383 |
| 58 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ames | Iowa | United States | 50010 |
| 59 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Louisville | Kentucky | United States | 40207 |
| 60 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Alexandria | Louisiana | United States | 71301 |
| 61 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Baton Rouge | Louisiana | United States | 70808 |
| 62 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Covington | Louisiana | United States | 70433 |
| 63 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lake Charles | Louisiana | United States | 70601 |
| 64 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Natchitoches | Louisiana | United States | 71457 |
| 65 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | New Orleans | Louisiana | United States | 70112 |
| 66 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Baltimore | Maryland | United States | 21287 |
| 67 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Salisbury | Maryland | United States | 21804 |
| 68 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Boston | Massachusetts | United States | 02135 |
| 69 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Fall River | Massachusetts | United States | 02720 |
| 70 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bay City | Michigan | United States | 48706 |
| 71 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Flint | Michigan | United States | 48532 |
| 72 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Minneapolis | Minnesota | United States | 55417 |
| 73 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Picayune | Mississippi | United States | 39466 |
| 74 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Columbia | Missouri | United States | 65201 |
| 75 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kansas City | Missouri | United States | 64111 |
| 76 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | St Louis | Missouri | United States | 63128 |
| 77 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kalispell | Montana | United States | 59901 |
| 78 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Omaha | Nebraska | United States | 68198 |
| 79 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Las Vegas | Nevada | United States | 89148 |
| 80 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nashua | New Hampshire | United States | 03060 |
| 81 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bridgewater | New Jersey | United States | 08807 |
| 82 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cherry Hill | New Jersey | United States | 08002 |
| 83 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Flemington | New Jersey | United States | 08822 |
| 84 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ridgewood | New Jersey | United States | 07652 |
| 85 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bronx | New York | United States | 10461 |
| 86 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Brooklyn | New York | United States | 11220 |
| 87 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Buffalo | New York | United States | 14215 |
| 88 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Flushing | New York | United States | 11355 |
| 89 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | New Hartford | New York | United States | 13413 |
| 90 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | New York | New York | United States | 10016 |
| 91 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Syracuse | New York | United States | 13210 |
| 92 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chapel Hill | North Carolina | United States | 27599 |
| 93 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Charlotte | North Carolina | United States | 28204 |
| 94 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Elizabeth City | North Carolina | United States | 27909 |
| 95 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gastonia | North Carolina | United States | 28054 |
| 96 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hickory | North Carolina | United States | 28601 |
| 97 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lenoir | North Carolina | United States | 28645 |
| 98 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Matthews | North Carolina | United States | 28105 |
| 99 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pinehurst | North Carolina | United States | 28374 |
| 100 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Salisbury | North Carolina | United States | 28144 |
| 101 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sanford | North Carolina | United States | 27330 |
| 102 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Statesville | North Carolina | United States | 28677 |
| 103 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wilmington | North Carolina | United States | 28403 |
| 104 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Winston Salem | North Carolina | United States | 27157 |
| 105 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cincinnati | Ohio | United States | 45220 |
| 106 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cleveland | Ohio | United States | 44106 |
| 107 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mansfield | Ohio | United States | 44906 |
| 108 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Toledo | Ohio | United States | 43608 |
| 109 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zanesville | Ohio | United States | 43701 |
| 110 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Muskogee | Oklahoma | United States | 74401 |
| 111 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Oklahoma City | Oklahoma | United States | 73104 |
| 112 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tulsa | Oklahoma | United States | 74104 |
| 113 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hillsboro | Oregon | United States | 97123 |
| 114 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Portland | Oregon | United States | 97220 |
| 115 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Abington | Pennsylvania | United States | 19001 |
| 116 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bethlehem | Pennsylvania | United States | 18015 |
| 117 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chambersburg | Pennsylvania | United States | 17201 |
| 118 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Clarks Summit | Pennsylvania | United States | 18411 |
| 119 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Doylestown | Pennsylvania | United States | 18901 |
| 120 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Erie | Pennsylvania | United States | 16502 |
| 121 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Greensburg | Pennsylvania | United States | 15601 |
| 122 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Harrisburg | Pennsylvania | United States | 17110 |
| 123 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pittsburgh | Pennsylvania | United States | 15240 |
| 124 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pottstown | Pennsylvania | United States | 19464 |
| 125 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sayre | Pennsylvania | United States | 18840 |
| 126 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sellersville | Pennsylvania | United States | 18960 |
| 127 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | West Chester | Pennsylvania | United States | 19380 |
| 128 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wormleysburg | Pennsylvania | United States | 17043 |
| 129 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Charleston | South Carolina | United States | 29425 |
| 130 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rock Hill | South Carolina | United States | 29732 |
| 131 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rapid City | South Dakota | United States | 57701 |
| 132 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sioux Falls | South Dakota | United States | 57104 |
| 133 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chattanooga | Tennessee | United States | 37404 |
| 134 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Germantown | Tennessee | United States | 38138 |
| 135 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hendersonville | Tennessee | United States | 37075 |
| 136 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jackson | Tennessee | United States | 38301 |
| 137 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Johnson City | Tennessee | United States | 37601 |
| 138 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Knoxville | Tennessee | United States | 37917 |
| 139 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lexington | Tennessee | United States | 38351 |
| 140 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Memphis | Tennessee | United States | 38120 |
| 141 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Oak Ridge | Tennessee | United States | 37830 |
| 142 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Amarillo | Texas | United States | 79106 |
| 143 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Austin | Texas | United States | 78745 |
| 144 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Corpus Christi | Texas | United States | 78404 |
| 145 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Edinburg | Texas | United States | 78539 |
| 146 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Fort Sam Houston | Texas | United States | 78234 |
| 147 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Houston | Texas | United States | 77089 |
| 148 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lackland Afb | Texas | United States | 78236 |
| 149 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Antonio | Texas | United States | 78201 |
| 150 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Victoria | Texas | United States | 77901 |
| 151 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | American Fork | Utah | United States | 84003 |
| 152 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Salt Lake City | Utah | United States | 84124 |
| 153 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Charlottesville | Virginia | United States | 22908 |
| 154 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Danville | Virginia | United States | 24541 |
| 155 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hopewell | Virginia | United States | 23860 |
| 156 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lake Ridge | Virginia | United States | 22192 |
| 157 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Manassas | Virginia | United States | 20109 |
| 158 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Newport News | Virginia | United States | 23601 |
| 159 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Richmond | Virginia | United States | 23298 |
| 160 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Roanoke | Virginia | United States | 24014 |
| 161 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Seattle | Washington | United States | 98122 |
| 162 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Spokane | Washington | United States | 99204 |
| 163 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tacoma | Washington | United States | 98405 |
| 164 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Burlington | Wisconsin | United States | 53105 |
| 165 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Milwaukee | Wisconsin | United States | 53215 |
| 166 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bahia Blanca | Argentina | B8001DDU | |
| 167 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Buenos Aires | Argentina | 1094 | |
| 168 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Caba | Argentina | C1180AAX | |
| 169 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Concordia | Argentina | E3202BQF | |
| 170 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Corrientes | Argentina | 3400 | |
| 171 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Córdoba | Argentina | X5000JHQ | |
| 172 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Formosa | Argentina | 3606 | |
| 173 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Godoy Cruz | Argentina | 5501 | |
| 174 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | La Plata | Argentina | B1900AVS | |
| 175 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mar Del Plata | Argentina | B7600FZD | |
| 176 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Moron | Argentina | B1708KCH | |
| 177 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rosario | Argentina | S2002KDS | |
| 178 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Salta | Argentina | A4402DTC | |
| 179 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Luis | Argentina | D5702JRS | |
| 180 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Miguel De Tucuman | Argentina | T4000NIL | |
| 181 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Santa Fe | Argentina | S3000FUJ | |
| 182 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Villa Cabrera | Argentina | S5009BSN | |
| 183 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Villa Maria | Argentina | X5900JKA | |
| 184 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Coffs Harbour | New South Wales | Australia | 2450 |
| 185 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lismore | New South Wales | Australia | 2480 |
| 186 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Newcastle | New South Wales | Australia | 2305 |
| 187 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wollongong | New South Wales | Australia | 2500 |
| 188 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Herston | Queensland | Australia | 4029 |
| 189 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nambour | Queensland | Australia | 4560 |
| 190 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Redcliffe | Queensland | Australia | 4020 |
| 191 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Southport | Queensland | Australia | 4215 |
| 192 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bedford Park | South Australia | Australia | 5042 |
| 193 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Elizabeth Vale | South Australia | Australia | 5112 |
| 194 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hobart | Tasmania | Australia | 7000 |
| 195 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Feldkirch | Austria | 6807 | |
| 196 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vienna | Austria | 1100 | |
| 197 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Brussels | Belgium | 1200 | |
| 198 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Huy | Belgium | 4500 | |
| 199 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Liège | Belgium | 4000 | |
| 200 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mol | Belgium | 2400 | |
| 201 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Overpelt | Belgium | 3900 | |
| 202 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Aracaju | Brazil | 49015-400 | |
| 203 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Belo Horizonte | Brazil | 30380-090 | |
| 204 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Blumenau | Brazil | 89010-500 | |
| 205 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Brasilia | Brazil | 70658-700 | |
| 206 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Campina Grande Do Sul | Brazil | 83430-000 | |
| 207 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Campinas | Brazil | 13010-001 | |
| 208 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Campo Grande | Brazil | 79080-190 | |
| 209 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Caxias Do Sul | Brazil | 95070560 | |
| 210 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Curitiba | Brazil | 80010-030 | |
| 211 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dois Lajeados | Brazil | 95900-000 | |
| 212 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Goiania | Brazil | 74223-130 | |
| 213 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Maceio | Brazil | 57021-500 | |
| 214 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Maringa | Brazil | 87015-290 | |
| 215 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Passo Fundo | Brazil | 99010-080 | |
| 216 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Piracicaba | Brazil | 13405-126 | |
| 217 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Porto Alegre | Brazil | 91350-200 | |
| 218 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Recife | Brazil | 52051-380 | |
| 219 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ribeirao Preto | Brazil | 14048-900 | |
| 220 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rio De Janeiro | Brazil | 21041-030 | |
| 221 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Salvador | Brazil | 41144900 | |
| 222 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Santo Andre | Brazil | 09190-610 | |
| 223 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sao Caetano Do Sul | Brazil | 09540-400 | |
| 224 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sao Jose Rio Preto | Brazil | 15090-000 | |
| 225 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sao Jose | Brazil | 88103-460 | |
| 226 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | São Paulo | Brazil | 05017000 | |
| 227 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Uberlandia | Brazil | 38400-368 | |
| 228 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Votuporanga | Brazil | 15500-003 | |
| 229 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dimitrovgrad | Bulgaria | 6400 | |
| 230 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Haskovo | Bulgaria | 6300 | |
| 231 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kazanlak | Bulgaria | 6100 | |
| 232 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kjustendil | Bulgaria | 2500 | |
| 233 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pazardzhik | Bulgaria | 4400 | |
| 234 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pleven | Bulgaria | 5800 | |
| 235 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Plovdiv | Bulgaria | 4002 | |
| 236 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rousse | Bulgaria | 7002 | |
| 237 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sofia | Bulgaria | 1606 | |
| 238 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Varna | Bulgaria | 9010 | |
| 239 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Edmonton | Alberta | Canada | T6K 4C1 |
| 240 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Campbell River | British Columbia | Canada | V9W 5Y4 |
| 241 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | St Johns | Newfoundland and Labrador | Canada | A1B 3V6 |
| 242 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Halifax | Nova Scotia | Canada | B3H 3A7 |
| 243 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ajax | Ontario | Canada | L1S 2J5 |
| 244 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Burlington | Ontario | Canada | L7M 4Y1 |
| 245 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cambridge | Ontario | Canada | N1R 7R1 |
| 246 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | London | Ontario | Canada | N6A 5A5 |
| 247 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Oshawa | Ontario | Canada | L1H 1B9 |
| 248 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sarnia | Ontario | Canada | N7T 4R9 |
| 249 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Scarborough | Ontario | Canada | M1E 5E9 |
| 250 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sudbury | Ontario | Canada | P3E 2N8 |
| 251 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Montreal | Quebec | Canada | H3G 1A4 |
| 252 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sainte-Foy | Quebec | Canada | G1V 4G5 |
| 253 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | La Serena | Chile | ||
| 254 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Osorno | Chile | 5290000 | |
| 255 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Puente Alto | Chile | 8207257 | |
| 256 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rancagua | Chile | ||
| 257 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Santiago | Chile | 8900085 | |
| 258 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Temuco | Chile | 478-1151 | |
| 259 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vina Del Mar | Chile | ||
| 260 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Beijing | China | 100730 | |
| 261 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bejing | China | 100032 | |
| 262 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Changsha | China | 410013 | |
| 263 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Fuzhou | China | 350001 | |
| 264 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Guang Zhou | China | 510120 | |
| 265 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hangzhou | China | 310013 | |
| 266 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Harbin | China | 150001 | |
| 267 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jiangsu | China | 210009 | |
| 268 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nanchang | China | ||
| 269 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nanjing | China | 210008 | |
| 270 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Shanghai | China | 200032 | |
| 271 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Shaoguan | China | 512026 | |
| 272 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Shengyang | China | 110004 | |
| 273 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Shenyang | China | 110001 | |
| 274 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Shijiazhuang | China | 050050 | |
| 275 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Suzhou City | China | 215004 | |
| 276 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wenzhou | China | 325027 | |
| 277 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wu Han | China | 430060 | |
| 278 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wuhan City | China | 430030 | |
| 279 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Xian | China | 710061 | |
| 280 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Xuzhou | China | 221006 | |
| 281 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zhengzhou | China | 450003 | |
| 282 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Armenia-Quindio | Colombia | ||
| 283 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Barranquilla | Colombia | ||
| 284 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bogota | Colombia | ||
| 285 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cali | Colombia | ||
| 286 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Floridablanca | Colombia | ||
| 287 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Medellin | Colombia | ||
| 288 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Jose | Costa Rica | ||
| 289 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dubrovnik | Croatia | 20000 | |
| 290 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Karlovac | Croatia | 47000 | |
| 291 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Koprivnica | Croatia | 48000 | |
| 292 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Krapinske Toplice | Croatia | 49217 | |
| 293 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rijeka | Croatia | 51 000 | |
| 294 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Slavonski Brod | Croatia | 35 000 | |
| 295 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Split | Croatia | 21000 | |
| 296 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Varazdin | Croatia | 42 000 | |
| 297 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zadar | Croatia | 23000 | |
| 298 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zagreb | Croatia | 10000 | |
| 299 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Decin | Czech Republic | 405 99 | |
| 300 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Frydek-Mistek | Czech Republic | 738 18 | |
| 301 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hradec Kralove | Czech Republic | 500 05 | |
| 302 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Karlovy Vary | Czech Republic | 360 66 | |
| 303 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kromeriz | Czech Republic | 767 55 | |
| 304 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Liberec | Czech Republic | 460 03 | |
| 305 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Novy Jicin | Czech Republic | 74101 | |
| 306 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pardubice | Czech Republic | 532 03 | |
| 307 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Prague | Czech Republic | 140 21 | |
| 308 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zlin | Czech Republic | 76275 | |
| 309 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Copenhagen | Denmark | 2300 | |
| 310 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hellerup | Denmark | 2900 | |
| 311 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kobenhavn | Denmark | 2400 | |
| 312 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Alexandria | Egypt | 21131 | |
| 313 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Beni Sweif | Egypt | ||
| 314 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cairo | Egypt | ||
| 315 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ismailia | Egypt | ||
| 316 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Menoufiya | Egypt | ||
| 317 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jyvaskyla | Finland | 40620 | |
| 318 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Angers | France | 49933 | |
| 319 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Arras | France | 62000 | |
| 320 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Besancon | France | 25030 | |
| 321 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cambrai | France | 59407 | |
| 322 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chartres Cedex | France | 28018 | |
| 323 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dijon | France | 21079 | |
| 324 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Douai | France | 59507 | |
| 325 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | La Roche Sur Yon | France | 85025 | |
| 326 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lagny Sur Marne | France | 77405 | |
| 327 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nantes | France | 44277 | |
| 328 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nice | France | 06002 | |
| 329 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Paris | France | 75015 | |
| 330 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pessac | France | 33604 | |
| 331 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Poitiers | France | 86021 | |
| 332 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Strasbourg | France | 67091 | |
| 333 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Toulouse | France | 31059 | |
| 334 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Valenciennes | France | 59322 | |
| 335 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vandoeuvre Les Nancy | France | 54511 | |
| 336 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bad Nauheim | Germany | 61231 | |
| 337 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Darmstadt | Germany | 64283 | |
| 338 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dortmund | Germany | 44137 | |
| 339 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Frankfurt | Germany | 65929 | |
| 340 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Halle | Germany | 06120 | |
| 341 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Idar-Oberstein | Germany | 55743 | |
| 342 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Köln | Germany | 50968 | |
| 343 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Leipzig | Germany | 04289 | |
| 344 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mainz | Germany | 55131 | |
| 345 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mannheim | Germany | 68167 | |
| 346 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Stuttgart | Germany | 70376 | |
| 347 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tuebingen | Germany | 72076 | |
| 348 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Athens | Greece | 16673 | |
| 349 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Haidari/Athens | Greece | 12462 | |
| 350 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kallithea | Greece | 17674 | |
| 351 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Magoula | Greece | 19600 | |
| 352 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Patras | Greece | 26504 | |
| 353 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rhodos | Greece | 85100 | |
| 354 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Trikala | Greece | 42100 | |
| 355 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Baja | Hungary | 6500 | |
| 356 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bekescsaba | Hungary | 5601 | |
| 357 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Budapest | Hungary | 1125 | |
| 358 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kalocsa | Hungary | 6300 | |
| 359 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kecskemet | Hungary | 6000 | |
| 360 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Komarom | Hungary | 2921 | |
| 361 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Miskolc | Hungary | H-3529 | |
| 362 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Satoraljaujhely | Hungary | H-3980 | |
| 363 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sopron | Hungary | 9400 | |
| 364 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Szekszard | Hungary | 7100 | |
| 365 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zalaegerszeg | Hungary | 8900 | |
| 366 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ahmedabad | India | 382 428 | |
| 367 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Anand | India | 388325 | |
| 368 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Aurangabad | India | 431001 | |
| 369 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bangalore | India | 560034 | |
| 370 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Baramati | India | 413102 | |
| 371 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bikaner | India | 334003 | |
| 372 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Calicut | India | 673004 | |
| 373 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chidambaram | India | 608002 | |
| 374 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cochin | India | 683572 | |
| 375 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Coimbatore | India | 641004 | |
| 376 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ernakulam | India | 683577 | |
| 377 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Guntur | India | 522001 | |
| 378 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gurgaon | India | 122001 | |
| 379 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hyderabaad | India | 500001 | |
| 380 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Indore | India | 452018 | |
| 381 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jaipur | India | 302017 | |
| 382 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jalandhar | India | 144008 | |
| 383 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kolkata | India | 700091 | |
| 384 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kottayam | India | 686016 | |
| 385 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lucknow | India | 226003 | |
| 386 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Madurai | India | 625020 | |
| 387 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mumbai | India | 400012 | |
| 388 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mysore | India | 570004 | |
| 389 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nagpur | India | 440033 | |
| 390 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nashik | India | 422005 | |
| 391 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | New Delhi | India | 110015 | |
| 392 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Patiala | India | 147001 | |
| 393 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pune | India | 411033 | |
| 394 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Saket | India | 110017 | |
| 395 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Secunderabad | India | 500 003 | |
| 396 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Shivamogga | India | 577201 | |
| 397 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Solapur | India | 413003 | |
| 398 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Surat | India | 395007 | |
| 399 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Thrissur | India | 680002 | |
| 400 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tirupati | India | 517 507 | |
| 401 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Trivandrum | India | 695002 | |
| 402 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vadodara | India | 390015 | |
| 403 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vijayawada | India | 520008 | |
| 404 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Visakhapatnam | India | 530 003 | |
| 405 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dublin | Ireland | ||
| 406 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Galway | Ireland | ||
| 407 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Afula | Israel | 18101 | |
| 408 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ashkelon | Israel | 78278 | |
| 409 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Beer Sheva | Israel | 84101 | |
| 410 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Eilat | Israel | 88104 | |
| 411 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Haifa | Israel | 31096 | |
| 412 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jerusalem | Israel | 91240 | |
| 413 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kfar Saba | Israel | 44281 | |
| 414 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nahariya | Israel | 22100 | |
| 415 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nazareth | Israel | 16100 | |
| 416 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rehovot | Israel | 76100 | |
| 417 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tel Aviv | Israel | 64239 | |
| 418 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tel Hashomer | Israel | 52621 | |
| 419 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tiberias | Israel | 15208 | |
| 420 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tzfat | Israel | 13100 | |
| 421 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Albano Laziale | Italy | 00041 | |
| 422 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ascoli Piceno | Italy | 63100 | |
| 423 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bari | Italy | 70124 | |
| 424 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bergamo | Italy | 24128 | |
| 425 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Brescia | Italy | 25127 | |
| 426 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Caserta | Italy | 81100 | |
| 427 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Forli | Italy | 47100 | |
| 428 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lecco | Italy | 23900 | |
| 429 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Legnago | Italy | 37045 | |
| 430 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Legnano | Italy | 20025 | |
| 431 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Milano | Italy | 20162 | |
| 432 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Novara | Italy | 28100 | |
| 433 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Parma | Italy | 43100 | |
| 434 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Perugia | Italy | 06156 | |
| 435 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pescara | Italy | 65124 | |
| 436 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Reggio Emilia | Italy | 42100 | |
| 437 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rimini | Italy | 47900 | |
| 438 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rome | Italy | 00161 | |
| 439 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Daniele Del Friuli | Italy | 33038 | |
| 440 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Santa Maria Capua Vetere | Italy | 81055 | |
| 441 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Saronno | Italy | 21047 | |
| 442 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sorrento | Italy | 80067 | |
| 443 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Terni | Italy | 5100 | |
| 444 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Trieste | Italy | 34142 | |
| 445 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Busan | Korea, Republic of | 614-735 | |
| 446 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Daegu | Korea, Republic of | 705-718 | |
| 447 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Daejeon | Korea, Republic of | 302-718 | |
| 448 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gangwon-Do | Korea, Republic of | 220-701 | |
| 449 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gwangju | Korea, Republic of | 501-757 | |
| 450 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Incheon | Korea, Republic of | 405-760 | |
| 451 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jeon Ju-City | Korea, Republic of | 561-712 | |
| 452 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jin-Ju-Si | Korea, Republic of | 660-702 | |
| 453 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Seoul | Korea, Republic of | 120-752 | |
| 454 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ulsan-Si | Korea, Republic of | 682-714 | |
| 455 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kaunas | Lithuania | LT-50009 | |
| 456 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Klaipeda | Lithuania | 92288 | |
| 457 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Siauliai | Lithuania | 73231 | |
| 458 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vilnius | Lithuania | LT-08661 | |
| 459 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cheras, Kuala Lumpur | Malaysia | 56000 | |
| 460 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Johor Bahru | Malaysia | 80100 | |
| 461 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kelantan | Malaysia | 16150 | |
| 462 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kuala Lumpur | Malaysia | 59100 | |
| 463 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kuantan Pahang | Malaysia | 25100 | |
| 464 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Perak | Malaysia | 30990 | |
| 465 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sarawak | Malaysia | 93586 | |
| 466 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Selangor | Malaysia | 43300 | |
| 467 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Taiping Perak | Malaysia | 34000 | |
| 468 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gozo | Malta | VCT102 | |
| 469 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Msida | Malta | 2090 | |
| 470 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Aguascalientes | Mexico | 20230 | |
| 471 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Culiacan | Mexico | 80270 | |
| 472 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Durango | Mexico | 340000 | |
| 473 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Jalisco | Mexico | 44210 | |
| 474 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Leon | Mexico | 37660 | |
| 475 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Monterrey | Mexico | 64020 | |
| 476 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Puebla | Mexico | 72490 | |
| 477 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Queretaro | Mexico | 76180 | |
| 478 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Luis Potosi | Mexico | 78240 | |
| 479 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tijuana | Mexico | 22500 | |
| 480 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Alkmaar | Netherlands | 1815 JD | |
| 481 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Almelo | Netherlands | 7609 PP | |
| 482 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Amsterdam | Netherlands | 1091AC | |
| 483 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Apeldoorn | Netherlands | 7334 DZ | |
| 484 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Beverwijk | Netherlands | 1942 LE | |
| 485 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Blaricum | Netherlands | 1261 AN | |
| 486 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Delft | Netherlands | 2625AD | |
| 487 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ede | Netherlands | 6716 RP | |
| 488 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Eindhoven | Netherlands | 5623 EJ | |
| 489 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gouda | Netherlands | 2803 HH | |
| 490 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Hoorn | Netherlands | 1625 HV | |
| 491 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Leeuwarden | Netherlands | 8934 AD | |
| 492 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Leiden | Netherlands | 2334 CK | |
| 493 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Leiderdorp | Netherlands | 2353 GA | |
| 494 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Meppel | Netherlands | 7943 KA | |
| 495 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Oss | Netherlands | 5342 BT | |
| 496 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Roosendaal | Netherlands | 4708 AE | |
| 497 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Venlo | Netherlands | 5912 BL | |
| 498 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Auckland | New Zealand | 0622 | |
| 499 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Christchurch | New Zealand | 8011 | |
| 500 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nelson | New Zealand | 7010 | |
| 501 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wellington | New Zealand | 6022 | |
| 502 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cocle | Panama | ||
| 503 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | David | Panama | ||
| 504 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Panama | Panama | ||
| 505 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Arequipa | Peru | ||
| 506 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Callao | Peru | ||
| 507 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cuzco | Peru | ||
| 508 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lima | Peru | Lima 29 | |
| 509 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cagayan De De Oro | Philippines | 9000 | |
| 510 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cavite City | Philippines | 4114 | |
| 511 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Davao City | Philippines | 8000 | |
| 512 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Iloilo City | Philippines | 5000 | |
| 513 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Manila | Philippines | 1000 | |
| 514 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Marikina City | Philippines | ||
| 515 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Metro Manila | Philippines | 1503 | |
| 516 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pasig City | Philippines | 1605 | |
| 517 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Quezon City | Philippines | 1102 | |
| 518 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Quezon City | Philippines | 1110 | |
| 519 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bydgoszcz | Poland | 85-826 | |
| 520 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Elblag | Poland | 02-300 | |
| 521 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gdansk | Poland | 80-345 | |
| 522 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Katowice | Poland | 40-635 | |
| 523 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Koszalin | Poland | 75-581 | |
| 524 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Krakow | Poland | 31-501 | |
| 525 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kutno | Poland | 99-300 | |
| 526 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lodz | Poland | 94-255 | |
| 527 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lubin | Poland | 59-301 | |
| 528 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lublin | Poland | 20-954 | |
| 529 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Myslenice | Poland | 32-400 | |
| 530 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nowy Sacz | Poland | 33-300 | |
| 531 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Olawa | Poland | 55-200 | |
| 532 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Piotrkow Trybunalski | Poland | 97-300 | |
| 533 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pulawy | Poland | 24-100 | |
| 534 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ruda Slaska | Poland | 41-703 | |
| 535 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Skierniewice | Poland | 96-100 | |
| 536 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Szczecin | Poland | 71-531 | |
| 537 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Walbrzych | Poland | 58-309 | |
| 538 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Warsaw | Poland | 04-439 | |
| 539 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wejherowo | Poland | 84-200 | |
| 540 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wroclaw | Poland | 51-124 | |
| 541 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Aveiro | Portugal | 3814-501 | |
| 542 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Carnaxide | Portugal | 2790-134 | |
| 543 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Coimbra | Portugal | 3000-075 | |
| 544 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Leiria | Portugal | 2410-197 | |
| 545 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ponta Delgada | Portugal | 9500-370 | |
| 546 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Santarem | Portugal | 2005-177 | |
| 547 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Setubal | Portugal | 2910-446 | |
| 548 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vila Franca De Xira | Portugal | 5000-508 | |
| 549 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Caguas | Puerto Rico | 00725 | |
| 550 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mayaguez | Puerto Rico | 00680 | |
| 551 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Juan | Puerto Rico | 00921-3201 | |
| 552 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bacau | Romania | 600114 | |
| 553 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Baia Mare | Romania | 430110 | |
| 554 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Braila | Romania | 810249 | |
| 555 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Brasov | Romania | 500326 | |
| 556 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bucharest | Romania | ||
| 557 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Buzau | Romania | 120144 | |
| 558 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cluj-Napoca | Romania | 400006 | |
| 559 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Focsani | Romania | 620034 | |
| 560 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pitesti | Romania | 110084 | |
| 561 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Suceava | Romania | 7202237 | |
| 562 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Targoviste | Romania | 130083 | |
| 563 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Arkhangelsk | Russian Federation | 163045 | |
| 564 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gatchina | Russian Federation | 188300 | |
| 565 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kazan | Russian Federation | 420029 | |
| 566 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kemerovo | Russian Federation | 650002 | |
| 567 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Krasnoyarsk | Russian Federation | 660062 | |
| 568 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Moscow | Russian Federation | 127644 | |
| 569 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nizhny Novgorod | Russian Federation | 603005 | |
| 570 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Novokuznetsk | Russian Federation | 654057 | |
| 571 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Novosibirsk | Russian Federation | 630090 | |
| 572 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Omsk | Russian Federation | 644018 | |
| 573 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rostov-On-Don | Russian Federation | 344068 | |
| 574 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Saint Petersburg | Russian Federation | 197110 | |
| 575 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Saratov | Russian Federation | 410028 | |
| 576 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tomsk | Russian Federation | 634012 | |
| 577 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tyumen | Russian Federation | 625000 | |
| 578 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Belgrade | Serbia | 11040 | |
| 579 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kragujevac | Serbia | 34000 | |
| 580 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Niska Banja | Serbia | 18205 | |
| 581 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nis | Serbia | 18000 | |
| 582 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zemun | Serbia | 11080 | |
| 583 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Singapore | Singapore | 119074 | |
| 584 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bratislava | Slovakia | 83348 | |
| 585 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Levice | Slovakia | 934 01 | |
| 586 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Martin | Slovakia | 03601 | |
| 587 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nitra | Slovakia | 95001 | |
| 588 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nove Zamky | Slovakia | 94034 | |
| 589 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Presov | Slovakia | 08181 | |
| 590 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ruzomberok | Slovakia | 03426 | |
| 591 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zilina | Slovakia | 010 01 | |
| 592 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Alberton | South Africa | 1449 | |
| 593 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bloemfontein | South Africa | 9301 | |
| 594 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cape Town | South Africa | 7405 | |
| 595 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Durban | South Africa | 4071 | |
| 596 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | George | South Africa | 6529 | |
| 597 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Johannesburg | South Africa | 2193 | |
| 598 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Parktown West | South Africa | 2193 | |
| 599 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Somerset West | South Africa | 7129 | |
| 600 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Worcester | South Africa | 6850 | |
| 601 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Barcelona | Spain | 08227 | |
| 602 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Gerona | Spain | 17600 | |
| 603 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Málaga | Spain | 29010 | |
| 604 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Palma De Mallorca | Spain | 07198 | |
| 605 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Reus | Spain | 43201 | |
| 606 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | San Boi De Llobregat | Spain | 08830 | |
| 607 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sevilla | Spain | 41008 | |
| 608 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Valencia | Spain | 46014 | |
| 609 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bollnas | Sweden | 82181 | |
| 610 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Karlstad | Sweden | 65185 | |
| 611 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lund | Sweden | 22241 | |
| 612 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bellinzona | Switzerland | CH-6500 | |
| 613 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Winterthur | Switzerland | 8401 | |
| 614 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kaohsiung | Taiwan | 80756 | |
| 615 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Taipei | Taiwan | 220 | |
| 616 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bangkok | Thailand | 10700 | |
| 617 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chiang Mai | Thailand | 50200 | |
| 618 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Khon Kaen | Thailand | 40002 | |
| 619 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nakhon Ratchasima | Thailand | 30000 | |
| 620 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Pathumthani | Thailand | 12120 | |
| 621 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Udon Thani | Thailand | 41000 | |
| 622 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | La Marsa | Tunisia | 2046 | |
| 623 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Menzel Bourguiba | Tunisia | 7050 | |
| 624 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Monastir | Tunisia | 5000 | |
| 625 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sfax | Tunisia | 3051 | |
| 626 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sousse | Tunisia | 4054 | |
| 627 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tunis Monfleury | Tunisia | 1008 | |
| 628 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tunis | Tunisia | 2070 | |
| 629 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Adana | Turkey | 1330 | |
| 630 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ankara | Turkey | 06800 | |
| 631 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bolu | Turkey | 14280 | |
| 632 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bursa | Turkey | 16059 | |
| 633 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Edirne | Turkey | 22030 | |
| 634 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Erzurum | Turkey | 25050 | |
| 635 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Isparta | Turkey | 32100 | |
| 636 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Istanbul | Turkey | 34300 | |
| 637 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kocaeli | Turkey | 41380 | |
| 638 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Konya | Turkey | 42075 | |
| 639 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kırıkkale | Turkey | 71100 | |
| 640 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Samsun | Turkey | 55139 | |
| 641 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Trabzon | Turkey | 61080 | |
| 642 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cherkasy | Ukraine | 18009 | |
| 643 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dnipropetrovsk | Ukraine | 49006 | |
| 644 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Donetsk | Ukraine | 83114 | |
| 645 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Ivano-Frankivsk | Ukraine | 76018 | |
| 646 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kharkiv | Ukraine | 61176 | |
| 647 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kiev | Ukraine | 02660 | |
| 648 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kryvyy Rig | Ukraine | 50031 | |
| 649 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Kyiv | Ukraine | 3115 | |
| 650 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lugansk | Ukraine | 91045 | |
| 651 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lutsk | Ukraine | 43024 | |
| 652 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lviv | Ukraine | 79015 | |
| 653 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Mykolayiv | Ukraine | 54003 | |
| 654 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Odesa | Ukraine | 65025 | |
| 655 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Poltava | Ukraine | 36038 | |
| 656 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Simferopol | Ukraine | 95026 | |
| 657 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Vinnytsya | Ukraine | 21029 | |
| 658 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Zaporozhye | Ukraine | 69000 | |
| 659 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Stockton-On-Tees | Cleveland | United Kingdom | TS19 8PE |
| 660 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Torquay | Cnwll | United Kingdom | TQ2 7AA |
| 661 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Durham | County Durham | United Kingdom | DH1 5TW |
| 662 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chesterfield | Derbyshire | United Kingdom | S44 5BL |
| 663 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Plymouth | Devon | United Kingdom | PL6 8DH |
| 664 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Brighton | East Sussex | United Kingdom | BN2 5BE |
| 665 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Cottingham | East Yorkshire | United Kingdom | HU16 5JQ |
| 666 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Colchester | Essex | United Kingdom | C04 5JL |
| 667 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Romford | Essex | United Kingdom | RM7 0AG |
| 668 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | London | Greater London | United Kingdom | SE13 6LH |
| 669 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Southall | Greater London | United Kingdom | UB1 3HW |
| 670 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Newport | Gwent | United Kingdom | NP20 2UB |
| 671 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Portsmouth | Hampshire | United Kingdom | P06 3LY |
| 672 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Orpington | Kent | United Kingdom | BR6 8ND |
| 673 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lincoln | Lincolnshire | United Kingdom | LN2 5QY |
| 674 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wirral | Merseyside | United Kingdom | CH49 5PE |
| 675 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | York | North Yorkshire | United Kingdom | YO31 8HE |
| 676 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nottingham | Nottinghamshire | United Kingdom | NG5 1PD |
| 677 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Yeovil | Somerset | United Kingdom | BA21 4AT |
| 678 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dundee | Tays | United Kingdom | DD1 9SY |
| 679 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nuneaton | Warwickshire | United Kingdom | CV10 7BL |
| 680 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Warwick | Warwickshire | United Kingdom | CV34 5BW |
| 681 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Livingston | West Lothian | United Kingdom | EH54 6PP |
| 682 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Birmingham | West Midlands | United Kingdom | B75 7RR |
| 683 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dudley | West Midlands | United Kingdom | DY1 2HQ |
| 684 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | West Bromwich | West Midlands | United Kingdom | B71 4HJ |
| 685 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Wolverhampton | West Midlands | United Kingdom | WV10 0QP |
| 686 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bradford | West Yorkshire | United Kingdom | BD9 6RJ |
| 687 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Northampton | United Kingdom | NN1 5BD | |
| 688 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Sunderland | United Kingdom | SR4 7TP |
Sponsors and Collaborators
- Eli Lilly and Company
- Daiichi Sankyo Co., Ltd.
- Duke Clinical Research Institute
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UC/GMT - 5 hours, EST), Eli Lilly and Company
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00699998
Other Study ID Numbers:
- 11058
- H7T-MC-TABY(b)
First Posted:
Jun 18, 2008
Last Update Posted:
May 7, 2013
Last Verified:
Mar 1, 2013
Keywords provided by Eli Lilly and Company
Additional relevant MeSH terms:
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin : Low-dose aspirin, oral, as prescribed by physician through end of study Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Period Title: Overall Study | ||||
| STARTED | 3620 | 1043 | 3623 | 1040 |
| Received at Least 1 Dose of Study Drug | 3590 | 1033 | 3590 | 1027 |
| COMPLETED | 3421 | 957 | 3417 | 958 |
| NOT COMPLETED | 199 | 86 | 206 | 82 |
Baseline Characteristics
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older | Total |
|---|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel : 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Total of all reporting groups |
| Overall Participants | 3620 | 1043 | 3623 | 1040 | 9326 |
| Age (years) [Mean (Standard Deviation) ] | |||||
| Mean (Standard Deviation) [years] |
61.4
(8.55)
|
80.3
(4.29)
|
61.5
(8.38)
|
80.3
(4.39)
|
65.7
(11.02)
|
| Sex: Female, Male (Count of Participants) | |||||
| Female |
1309
36.2%
|
520
49.9%
|
1290
35.6%
|
531
51.1%
|
3650
39.1%
|
| Male |
2311
63.8%
|
523
50.1%
|
2333
64.4%
|
509
48.9%
|
5676
60.9%
|
| Race/Ethnicity, Customized (participants) [Number] | |||||
| Caucasian |
2362
65.2%
|
767
73.5%
|
2374
65.5%
|
773
74.3%
|
6276
67.3%
|
| African |
87
2.4%
|
14
1.3%
|
72
2%
|
12
1.2%
|
185
2%
|
| Hispanic |
321
8.9%
|
109
10.5%
|
346
9.6%
|
86
8.3%
|
862
9.2%
|
| Asian |
821
22.7%
|
147
14.1%
|
800
22.1%
|
164
15.8%
|
1932
20.7%
|
| Other |
29
0.8%
|
6
0.6%
|
30
0.8%
|
5
0.5%
|
70
0.8%
|
| Unknown |
0
0%
|
0
0%
|
1
0%
|
0
0%
|
1
0%
|
| Region of Enrollment (participants) [Number] | |||||
| Portugal |
18
0.5%
|
11
1.1%
|
14
0.4%
|
11
1.1%
|
54
0.6%
|
| Philippines |
58
1.6%
|
7
0.7%
|
48
1.3%
|
14
1.3%
|
127
1.4%
|
| Taiwan |
6
0.2%
|
6
0.6%
|
4
0.1%
|
9
0.9%
|
25
0.3%
|
| Slovakia |
62
1.7%
|
20
1.9%
|
60
1.7%
|
20
1.9%
|
162
1.7%
|
| Greece |
14
0.4%
|
8
0.8%
|
10
0.3%
|
11
1.1%
|
43
0.5%
|
| Costa Rica |
5
0.1%
|
1
0.1%
|
2
0.1%
|
2
0.2%
|
10
0.1%
|
| Thailand |
30
0.8%
|
17
1.6%
|
36
1%
|
10
1%
|
93
1%
|
| Ukraine |
326
9%
|
28
2.7%
|
311
8.6%
|
42
4%
|
707
7.6%
|
| Chile |
28
0.8%
|
15
1.4%
|
33
0.9%
|
13
1.3%
|
89
1%
|
| Italy |
71
2%
|
44
4.2%
|
70
1.9%
|
47
4.5%
|
232
2.5%
|
| India |
513
14.2%
|
56
5.4%
|
508
14%
|
64
6.2%
|
1141
12.2%
|
| France |
29
0.8%
|
22
2.1%
|
29
0.8%
|
19
1.8%
|
99
1.1%
|
| Denmark |
21
0.6%
|
7
0.7%
|
17
0.5%
|
10
1%
|
55
0.6%
|
| Korea, Republic of |
35
1%
|
7
0.7%
|
33
0.9%
|
7
0.7%
|
82
0.9%
|
| Panama |
29
0.8%
|
7
0.7%
|
24
0.7%
|
10
1%
|
70
0.8%
|
| Turkey |
76
2.1%
|
24
2.3%
|
81
2.2%
|
19
1.8%
|
200
2.1%
|
| Czech Republic |
37
1%
|
31
3%
|
32
0.9%
|
38
3.7%
|
138
1.5%
|
| Mexico |
38
1%
|
15
1.4%
|
40
1.1%
|
16
1.5%
|
109
1.2%
|
| Canada |
58
1.6%
|
14
1.3%
|
61
1.7%
|
13
1.3%
|
146
1.6%
|
| Brazil |
154
4.3%
|
27
2.6%
|
147
4.1%
|
34
3.3%
|
362
3.9%
|
| Romania |
103
2.8%
|
26
2.5%
|
105
2.9%
|
23
2.2%
|
257
2.8%
|
| Croatia |
63
1.7%
|
28
2.7%
|
60
1.7%
|
31
3%
|
182
2%
|
| Sweden |
4
0.1%
|
3
0.3%
|
6
0.2%
|
1
0.1%
|
14
0.2%
|
| United States |
430
11.9%
|
133
12.8%
|
446
12.3%
|
116
11.2%
|
1125
12.1%
|
| Serbia |
42
1.2%
|
4
0.4%
|
40
1.1%
|
5
0.5%
|
91
1%
|
| Spain |
13
0.4%
|
8
0.8%
|
10
0.3%
|
12
1.2%
|
43
0.5%
|
| Ireland |
5
0.1%
|
4
0.4%
|
6
0.2%
|
3
0.3%
|
18
0.2%
|
| Israel |
75
2.1%
|
33
3.2%
|
85
2.3%
|
21
2%
|
214
2.3%
|
| Russian Federation |
128
3.5%
|
22
2.1%
|
135
3.7%
|
14
1.3%
|
299
3.2%
|
| Colombia |
40
1.1%
|
21
2%
|
45
1.2%
|
17
1.6%
|
123
1.3%
|
| Switzerland |
6
0.2%
|
4
0.4%
|
4
0.1%
|
6
0.6%
|
20
0.2%
|
| Malaysia |
35
1%
|
7
0.7%
|
33
0.9%
|
9
0.9%
|
84
0.9%
|
| Peru |
58
1.6%
|
19
1.8%
|
67
1.8%
|
12
1.2%
|
156
1.7%
|
| Australia |
13
0.4%
|
6
0.6%
|
15
0.4%
|
7
0.7%
|
41
0.4%
|
| South Africa |
27
0.7%
|
11
1.1%
|
27
0.7%
|
12
1.2%
|
77
0.8%
|
| Netherlands |
55
1.5%
|
23
2.2%
|
53
1.5%
|
24
2.3%
|
155
1.7%
|
| Tunisia |
20
0.6%
|
3
0.3%
|
20
0.6%
|
4
0.4%
|
47
0.5%
|
| China |
126
3.5%
|
38
3.6%
|
120
3.3%
|
44
4.2%
|
328
3.5%
|
| Finland |
3
0.1%
|
3
0.3%
|
5
0.1%
|
2
0.2%
|
13
0.1%
|
| Lithuania |
29
0.8%
|
8
0.8%
|
32
0.9%
|
4
0.4%
|
73
0.8%
|
| Austria |
6
0.2%
|
6
0.6%
|
6
0.2%
|
5
0.5%
|
23
0.2%
|
| Malta |
9
0.2%
|
1
0.1%
|
10
0.3%
|
2
0.2%
|
22
0.2%
|
| United Kingdom |
33
0.9%
|
21
2%
|
40
1.1%
|
12
1.2%
|
106
1.1%
|
| Egypt |
65
1.8%
|
1
0.1%
|
62
1.7%
|
4
0.4%
|
132
1.4%
|
| Hungary |
86
2.4%
|
43
4.1%
|
87
2.4%
|
44
4.2%
|
260
2.8%
|
| Argentina |
120
3.3%
|
58
5.6%
|
138
3.8%
|
41
3.9%
|
357
3.8%
|
| Poland |
137
3.8%
|
59
5.7%
|
129
3.6%
|
68
6.5%
|
393
4.2%
|
| Belgium |
7
0.2%
|
7
0.7%
|
7
0.2%
|
8
0.8%
|
29
0.3%
|
| Singapore |
2
0.1%
|
5
0.5%
|
5
0.1%
|
1
0.1%
|
13
0.1%
|
| Bulgaria |
216
6%
|
48
4.6%
|
209
5.8%
|
55
5.3%
|
528
5.7%
|
| Germany |
46
1.3%
|
20
1.9%
|
46
1.3%
|
21
2%
|
133
1.4%
|
| New Zealand |
10
0.3%
|
3
0.3%
|
10
0.3%
|
3
0.3%
|
26
0.3%
|
| History of Diabetes (participants) [Number] | |||||
| Yes |
1393
38.5%
|
363
34.8%
|
1418
39.1%
|
365
35.1%
|
3539
37.9%
|
| No |
2221
61.4%
|
678
65%
|
2193
60.5%
|
675
64.9%
|
5767
61.8%
|
| Unknown |
6
0.2%
|
2
0.2%
|
12
0.3%
|
0
0%
|
20
0.2%
|
| History of Myocardial Infarction (MI) (participants) [Number] | |||||
| Yes |
1556
43%
|
426
40.8%
|
1612
44.5%
|
393
37.8%
|
3987
42.8%
|
| No |
2035
56.2%
|
603
57.8%
|
1988
54.9%
|
633
60.9%
|
5259
56.4%
|
| Unknown |
29
0.8%
|
14
1.3%
|
23
0.6%
|
14
1.3%
|
80
0.9%
|
| History of Coronary Revascularization (PCI or CABG) (participants) [Number] | |||||
| Yes |
1279
35.3%
|
330
31.6%
|
1365
37.7%
|
299
28.8%
|
3273
35.1%
|
| No |
2332
64.4%
|
703
67.4%
|
2239
61.8%
|
734
70.6%
|
6008
64.4%
|
| Unknown |
9
0.2%
|
10
1%
|
19
0.5%
|
7
0.7%
|
45
0.5%
|
| Clinical Presentation of UA or NSTEMI (participants) [Number] | |||||
| Unstable Angina |
963
26.6%
|
166
15.9%
|
981
27.1%
|
192
18.5%
|
2302
24.7%
|
| Non-ST-segment Elevation Myocardial Infarction |
2453
67.8%
|
829
79.5%
|
2434
67.2%
|
804
77.3%
|
6520
69.9%
|
| Unknown/Did not meet criteria |
204
5.6%
|
48
4.6%
|
208
5.7%
|
44
4.2%
|
504
5.4%
|
Outcome Measures
| Title | Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke |
|---|---|
| Description | The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. |
| Time Frame | Randomization through end of study (30-month visit) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 3620 | 1043 | 3623 | 1040 |
| Number [percentage of participants with an event] |
10.06
0.3%
|
24.64
2.4%
|
10.96
0.3%
|
24.13
2.3%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.210 |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.915 | |
| Confidence Interval |
(2-Sided) 95% 0.793 to 1.055 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.731 |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 1.029 | |
| Confidence Interval |
(2-Sided) 95% 0.865 to 1.225 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
| Title | Percentage of Participants With a Composite Endpoint of CV Death and MI |
|---|---|
| Description | The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. |
| Time Frame | Randomization through end of study (30-month visit) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 3620 | 1043 | 3623 | 1040 |
| Number [percentage of participants with an event] |
9.61
0.3%
|
22.53
2.2%
|
10.21
0.3%
|
22.69
2.2%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.388 |
| Comments | ||
| Method | Log Rank | |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.940 | |
| Confidence Interval |
(2-Sided) 95% 0.812 to 1.088 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.990 |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.998 | |
| Confidence Interval |
(2-Sided) 95% 0.833 to 1.195 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
| Title | Percentage of Participants With a Composite Endpoint of CV Death, MI, Stroke, or Re-hospitalization for Recurrent Unstable Angina (UA) |
|---|---|
| Description | The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. |
| Time Frame | Randomization through end of study (30-month visit) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 3620 | 1043 | 3623 | 1040 |
| Number [percentage of participants with an event] |
12.13
0.3%
|
26.27
2.5%
|
12.83
0.4%
|
25.67
2.5%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.353 |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.941 | |
| Confidence Interval |
(2-Sided) 95% 0.826 to 1.073 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.719 |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 1.029 | |
| Confidence Interval |
(2-Sided) 95% 0.869 to 1.218 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
| Title | Percentage of Participants With a Composite Endpoint of All-cause Death, MI, or Stroke |
|---|---|
| Description | The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. |
| Time Frame | Randomization through end of study (30-month visit) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 3620 | 1043 | 3623 | 1040 |
| Number [percentage of participants with an event] |
10.61
0.3%
|
27.04
2.6%
|
11.12
0.3%
|
26.83
2.6%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.270 |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.928 | |
| Confidence Interval |
(2-Sided) 95% 0.810 to 1.063 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.831 |
| Comments | Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization. | |
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 1.017 | |
| Confidence Interval |
(2-Sided) 95% 0.862 to 1.200 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | HR and two-sided 95% CI derived using Cox proportional hazards model with treatment and clopidogrel status at randomization as fixed effects. | |
| Title | Platelet Aggregation Measures |
|---|---|
| Description | Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. |
| Time Frame | Day 30 and 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received at least 1 dose of study drug, and had a baseline and post-baseline PRU measurement at Day 30 or Month 12. |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 720 | 158 | 683 | 179 |
| Day 30 |
93.280
(3.804)
|
151.872
(8.148)
|
193.489
(3.780)
|
200.285
(8.238)
|
| Month 12 (n=386, 76, 400, 103) |
94.529
(5.706)
|
135.096
(14.631)
|
199.003
(5.663)
|
181.360
(14.380)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | <0.001 |
| Comments | p-value is for Day 30 comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
| Estimated Value | -100.208 | |
| Confidence Interval |
(2-Sided) 95% -107.872 to -92.545 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Estimated Mean Difference (Final Values) for Day 30 comparison | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | <0.001 |
| Comments | p-value is for 12 month comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
| Estimated Value | -104.475 | |
| Confidence Interval |
(2-Sided) 95% -115.383 to -93.566 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Estimated Mean Difference (Final Values) for 12 month comparison. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | <0.001 |
| Comments | p-value is for 30 day comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
| Estimated Value | -48.413 | |
| Confidence Interval |
(2-Sided) 95% -63.718 to -33.108 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Estimated Mean Difference (Final Values) is for the 30 day comparison. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | <0.001 |
| Comments | p-value is for the 12 month comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
| Estimated Value | -46.264 | |
| Confidence Interval |
(2-Sided) 95% -69.061 to -23.468 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Estimated Mean Difference (Final Values) is for the 12 month comparison. | |
| Title | Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP) |
|---|---|
| Description | Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. |
| Time Frame | Day 30 and 6 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants who received at least 1 dose of study therapy and had baseline and post-baseline BNP measurement at Day 30 or 6 Months. |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 859 | 196 | 840 | 224 |
| Day 30 |
313.494
(1.039)
|
1082.396
(1.093)
|
319.345
(1.039)
|
951.359
(1.092)
|
| 6 Months (n=725, 125, 701, 174) |
253.434
(1.049)
|
770.132
(1.135)
|
250.982
(1.049)
|
722.750
(1.130)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.631 |
| Comments | p-value is for the 30 day comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 0.982 | |
| Confidence Interval |
(2-Sided) 95% 0.910 to 1.059 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 30 day comparison. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.844 |
| Comments | p-value is for the 6 month comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 1.010 | |
| Confidence Interval |
(2-Sided) 95% 0.916 to 1.113 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 6 month comparison. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.098 |
| Comments | p-value is for the 30 day comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 1.138 | |
| Confidence Interval |
(2-Sided) 95% 0.977 to 1.325 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 30 day comparison. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.545 |
| Comments | p-value is for the 6 month comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 1.066 | |
| Confidence Interval |
(2-Sided) 95% 0.867 to 1.310 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 6 month comparison. | |
| Title | Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP) |
|---|---|
| Description | C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. |
| Time Frame | Day 30 and Month 6 |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants who received at least 1 dose of study therapy and had baseline and post-baseline CRP measurement at Day 30 or 6 Months. |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 888 | 209 | 863 | 226 |
| Day 30 |
2.330
(1.053)
|
2.441
(1.150)
|
2.287
(1.053)
|
2.226
(1.150)
|
| 6 Months (n=755, 143, 745, 178) |
2.272
(1.060)
|
1.593
(1.173)
|
2.149
(1.059)
|
1.543
(1.170)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.727 |
| Comments | p-value is for the 30 day comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 1.018 | |
| Confidence Interval |
(2-Sided) 95% 0.919 to 1.129 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 30 day comparison. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Clopidogrel: <75 Years of Age |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.346 |
| Comments | p-value is for the 6 month comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 1.057 | |
| Confidence Interval |
(2-Sided) 95% 0.942 to 1.187 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 6 month comparison. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.458 |
| Comments | p-value is for the 30 day comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 1.096 | |
| Confidence Interval |
(2-Sided) 95% 0.859 to 1.399 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 30 day comparison. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: 75 Years of Age or Older, Clopidogrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.802 |
| Comments | p-value is for the 6 month comparison. ANCOVA Model: Measurement = treatment + baseline value + clopidogrel status at randomization. | |
| Method | ANCOVA | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Geometric Ratio Estimate |
| Estimated Value | 1.033 | |
| Confidence Interval |
(2-Sided) 95% 0.803 to 1.329 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Geometric Ratio Estimate is for the 6 month comparison. | |
| Title | Genotyping Related to Drug Metabolism |
|---|---|
| Description | Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. |
| Time Frame | Baseline |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants who provided a DNA sample. |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 2210 | 639 | 2237 | 650 |
| UM, *1/*17 |
24.0
0.7%
|
25.0
2.4%
|
25.1
0.7%
|
21.8
2.1%
|
| UM, *17/*17 |
5.1
0.1%
|
3.6
0.3%
|
5.4
0.1%
|
4.3
0.4%
|
| EM (non-UM), *1/*1 |
38.8
1.1%
|
42.1
4%
|
35.7
1%
|
41.2
4%
|
| IM, *1/*2 |
18.6
0.5%
|
18.3
1.8%
|
19.8
0.5%
|
19.7
1.9%
|
| IM, *1/*3 |
0.8
0%
|
0.6
0.1%
|
0.5
0%
|
0.6
0.1%
|
| IM, *1/*4 |
0.4
0%
|
0.0
0%
|
0.1
0%
|
0.3
0%
|
| IM, *1/*6 |
0.0
0%
|
0.2
0%
|
0.0
0%
|
0.2
0%
|
| IM, *1/*8 |
0.1
0%
|
0.5
0%
|
0.4
0%
|
0.3
0%
|
| PM, *2/*2 |
3.9
0.1%
|
2.2
0.2%
|
4.3
0.1%
|
3.8
0.4%
|
| PM, *2/*3 |
0.3
0%
|
0.2
0%
|
0.3
0%
|
0.3
0%
|
| PM, *2/*4 |
0.0
0%
|
0.2
0%
|
0.2
0%
|
0.2
0%
|
| PM, *2/*6 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
| PM, *2/*8 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
| PM, *3/*3 |
0.0
0%
|
0.0
0%
|
0.2
0%
|
0.0
0%
|
| UNK, *1/*10 |
0.0
0%
|
0.0
0%
|
0.1
0%
|
0.0
0%
|
| UNK, *1/*13 |
0.0
0%
|
0.2
0%
|
0.0
0%
|
0.0
0%
|
| UNK, *1/*9 |
0.1
0%
|
0.2
0%
|
0.0
0%
|
0.0
0%
|
| UNK, *1/*9, *9/*17 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
| UNK, *13/*17 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
| UNK, *2/*13 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
| UNK, *2/*17 |
6.3
0.2%
|
6.1
0.6%
|
6.8
0.2%
|
6.2
0.6%
|
| UNK, *2/*9 |
0.0
0%
|
0.0
0%
|
0.1
0%
|
0.0
0%
|
| UNK, *3/*17 |
0.1
0%
|
0.0
0%
|
0.0
0%
|
0.3
0%
|
| UNK, *4/*17 |
0.2
0%
|
0.2
0%
|
0.2
0%
|
0.0
0%
|
| UNK, *4/*9 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
| UNK, *6/*17 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.2
0%
|
| UNK, *8/*17 |
0.2
0%
|
0.0
0%
|
0.1
0%
|
0.0
0%
|
| UNK, *9/*17 |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
| UNK, Undefined genotype |
0.7
0%
|
0.6
0.1%
|
0.5
0%
|
0.6
0.1%
|
| Title | Economic and Quality of Life Outcomes |
|---|---|
| Description | Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. |
| Time Frame | Baseline and follow-up (24 months) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants (combined <75 years and 75 years and older) with SAQ data. |
| Arm/Group Title | Prasugrel | Clopidogrel |
|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 1506 | 1506 |
| Baseline, physical limitations |
67.8
(26.1)
|
67.0
(26.5)
|
| Baseline, angina frequency |
73.6
(22.9)
|
73.1
(23.5)
|
| 24 Months, physical limitations (n=420, 412) |
75.1
(24.4)
|
74.5
(25.7)
|
| 24 Months, angina frequency (n=420, 412) |
89.7
(20.0)
|
89.5
(19.1)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Prasugrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.5 |
| Comments | p-value is for the comparison of physical limitations at baseline. p-values are from a regression model with treatment group and the respective baseline quality-of-life measure as predictors. | |
| Method | ANCOVA | |
| Comments | ||
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Prasugrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.72 |
| Comments | p-value is for the comparison of angina frequency at baseline. p-values are from a regression model with treatment group and the respective baseline quality-of-life measure as predictors. | |
| Method | ANCOVA | |
| Comments | ||
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Prasugrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.63 |
| Comments | p-value is for the comparison of physical limitations at 24 months. p-values are from a regression model with treatment group and the respective baseline quality-of-life measure as predictors. | |
| Method | ANCOVA | |
| Comments | ||
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Prasugrel: <75 Years of Age, Prasugrel: 75 Years of Age or Older |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.53 |
| Comments | p-value is for the comparison of angina frequency at at 24 months. p-values are from a regression model with treatment group and the respective baseline quality-of-life measure as predictors. | |
| Method | ANCOVA | |
| Comments | ||
| Title | Summary of All Deaths |
|---|---|
| Description | All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. |
| Time Frame | Randomization through end of study (30-month visit) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants |
| Arm/Group Title | Prasugrel: <75 Years of Age | Prasugrel: 75 Years of Age or Older | Clopidogrel: <75 Years of Age | Clopidogrel: 75 Years of Age or Older |
|---|---|---|---|---|
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight) orally, once daily as maintenance dose through end of study. | Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg orally, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (<) 75 years of age. Commercially-available Aspirin : Low-dose aspirin, oral, as prescribed by physician through end of study Clopidogrel : 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study | Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. |
| Measure Participants | 3620 | 1043 | 3623 | 1040 |
| Congestive Heart Failure |
10
0.3%
|
21
2%
|
13
0.4%
|
23
2.2%
|
| Cardiogenic Shock |
8
0.2%
|
4
0.4%
|
10
0.3%
|
9
0.9%
|
| Cardiac Rupture |
0
0%
|
1
0.1%
|
0
0%
|
0
0%
|
| Myocardial Infarction |
16
0.4%
|
24
2.3%
|
24
0.7%
|
21
2%
|
| Dysrhythmia |
5
0.1%
|
2
0.2%
|
6
0.2%
|
3
0.3%
|
| Stent Thrombosis |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Directly Related to Revascularization-CABG or PCI |
1
0%
|
1
0.1%
|
1
0%
|
1
0.1%
|
| Intracranial Hemorrhage |
2
0.1%
|
1
0.1%
|
4
0.1%
|
1
0.1%
|
| Non-Hemorrhagic Stroke |
4
0.1%
|
4
0.4%
|
4
0.1%
|
3
0.3%
|
| Sudden death due to cardiovascular event |
75
2.1%
|
39
3.7%
|
70
1.9%
|
43
4.1%
|
| Pulmonary Embolism |
0
0%
|
1
0.1%
|
2
0.1%
|
1
0.1%
|
| Stroke, unknown type |
0
0%
|
1
0.1%
|
0
0%
|
0
0%
|
| Other Cardiovascular Event |
6
0.2%
|
1
0.1%
|
0
0%
|
1
0.1%
|
| Cardiovascular event, unknown type |
40
1.1%
|
41
3.9%
|
45
1.2%
|
45
4.3%
|
| Accidental |
1
0%
|
0
0%
|
1
0%
|
1
0.1%
|
| Trauma |
2
0.1%
|
3
0.3%
|
0
0%
|
1
0.1%
|
| Hemorrhage, not intracranial |
1
0%
|
1
0.1%
|
0
0%
|
4
0.4%
|
| Infection |
14
0.4%
|
21
2%
|
16
0.4%
|
17
1.6%
|
| Malignancy |
14
0.4%
|
7
0.7%
|
14
0.4%
|
11
1.1%
|
| Suicide |
1
0%
|
0
0%
|
0
0%
|
0
0%
|
| Other Non-Cardiovascular event |
8
0.2%
|
4
0.4%
|
8
0.2%
|
6
0.6%
|
| Cause unknown (nonadjudicated event) |
0
0%
|
1
0.1%
|
0
0%
|
0
0%
|
Adverse Events
| Time Frame | ||||
|---|---|---|---|---|
| Adverse Event Reporting Description | Events leading to death, MI, stroke, stent thrombosis, or rehospitalization for recurrent UA were not recorded as an SAEs unless the event was possibly due to study drug. | |||
| Arm/Group Title | Prasugrel | Clopidogrel | ||
| Arm/Group Description | Prasugrel and Low-dose Commercially-available Aspirin in participants. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study Prasugrel: 30 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study. | Clopidogrel and Low-Dose Commercially-available Aspirin in participants. Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study. Clopidogrel: 300 milligram (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study. | ||
All Cause Mortality |
||||
| Prasugrel | Clopidogrel | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Prasugrel | Clopidogrel | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 1573/4623 (34%) | 1594/4617 (34.5%) | ||
| Blood and lymphatic system disorders | ||||
| Anaemia | 23/4623 (0.5%) | 23 | 23/4617 (0.5%) | 23 |
| Anaemia haemolytic autoimmune | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Autoimmune thrombocytopenia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Bicytopenia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Coagulopathy | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Haemorrhagic anaemia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hypochromic anaemia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Iron deficiency anaemia | 3/4623 (0.1%) | 3 | 5/4617 (0.1%) | 5 |
| Microcytic anaemia | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Normochromic normocytic anaemia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pancytopenia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Red blood cell abnormality | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Splenic infarction | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Thrombocytopenia | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Cardiac disorders | ||||
| Acute coronary syndrome | 17/4623 (0.4%) | 17 | 19/4617 (0.4%) | 24 |
| Acute left ventricular failure | 8/4623 (0.2%) | 11 | 9/4617 (0.2%) | 10 |
| Acute myocardial infarction | 194/4623 (4.2%) | 241 | 194/4617 (4.2%) | 244 |
| Angina pectoris | 115/4623 (2.5%) | 125 | 129/4617 (2.8%) | 139 |
| Angina unstable | 290/4623 (6.3%) | 351 | 310/4617 (6.7%) | 374 |
| Aortic valve disease | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Aortic valve incompetence | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Aortic valve stenosis | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Arrhythmia | 7/4623 (0.2%) | 7 | 2/4617 (0%) | 2 |
| Arrhythmia supraventricular | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Arteriosclerosis coronary artery | 4/4623 (0.1%) | 4 | 4/4617 (0.1%) | 4 |
| Arteriospasm coronary | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Atrial fibrillation | 82/4623 (1.8%) | 88 | 69/4617 (1.5%) | 71 |
| Atrial flutter | 12/4623 (0.3%) | 12 | 4/4617 (0.1%) | 5 |
| Atrial tachycardia | 2/4623 (0%) | 2 | 3/4617 (0.1%) | 3 |
| Atrial thrombosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Atrioventricular block | 3/4623 (0.1%) | 3 | 6/4617 (0.1%) | 7 |
| Atrioventricular block complete | 2/4623 (0%) | 2 | 5/4617 (0.1%) | 5 |
| Atrioventricular block second degree | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Bradyarrhythmia | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Bradycardia | 7/4623 (0.2%) | 8 | 14/4617 (0.3%) | 14 |
| Bundle branch block left | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Bundle branch block right | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cardiac arrest | 29/4623 (0.6%) | 30 | 28/4617 (0.6%) | 28 |
| Cardiac disorder | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cardiac failure | 68/4623 (1.5%) | 75 | 67/4617 (1.5%) | 81 |
| Cardiac failure acute | 12/4623 (0.3%) | 12 | 19/4617 (0.4%) | 19 |
| Cardiac failure chronic | 36/4623 (0.8%) | 36 | 41/4617 (0.9%) | 41 |
| Cardiac failure congestive | 83/4623 (1.8%) | 96 | 104/4617 (2.3%) | 111 |
| Cardiac flutter | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cardiac tamponade | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cardiac valve disease | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cardio-respiratory arrest | 8/4623 (0.2%) | 8 | 14/4617 (0.3%) | 14 |
| Cardiogenic shock | 15/4623 (0.3%) | 15 | 23/4617 (0.5%) | 23 |
| Cardiomegaly | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cardiomyopathy | 3/4623 (0.1%) | 3 | 1/4617 (0%) | 1 |
| Cardiopulmonary failure | 5/4623 (0.1%) | 5 | 3/4617 (0.1%) | 3 |
| Cardiovascular insufficiency | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Congestive cardiomyopathy | 2/4623 (0%) | 2 | 1/4617 (0%) | 2 |
| Cor pulmonale | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Coronary artery disease | 43/4623 (0.9%) | 43 | 39/4617 (0.8%) | 39 |
| Coronary artery dissection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Coronary artery occlusion | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Coronary artery perforation | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Coronary artery stenosis | 8/4623 (0.2%) | 8 | 7/4617 (0.2%) | 7 |
| Coronary artery thrombosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Diastolic dysfunction | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ischaemic cardiomyopathy | 4/4623 (0.1%) | 4 | 3/4617 (0.1%) | 3 |
| Left ventricular dysfunction | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Left ventricular failure | 4/4623 (0.1%) | 4 | 8/4617 (0.2%) | 8 |
| Low cardiac output syndrome | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Mitral valve disease | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Mitral valve incompetence | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Myocardial fibrosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Myocardial infarction | 142/4623 (3.1%) | 166 | 143/4617 (3.1%) | 166 |
| Myocardial ischaemia | 31/4623 (0.7%) | 31 | 41/4617 (0.9%) | 41 |
| Palpitations | 2/4623 (0%) | 2 | 3/4617 (0.1%) | 3 |
| Pericardial effusion | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Pericarditis | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Postinfarction angina | 5/4623 (0.1%) | 5 | 4/4617 (0.1%) | 4 |
| Prinzmetal angina | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Sick sinus syndrome | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Sinus arrest | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Sinus bradycardia | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Stress cardiomyopathy | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Supraventricular tachycardia | 4/4623 (0.1%) | 4 | 8/4617 (0.2%) | 8 |
| Tachycardia | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Ventricle rupture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Ventricular arrhythmia | 4/4623 (0.1%) | 4 | 0/4617 (0%) | 0 |
| Ventricular extrasystoles | 2/4623 (0%) | 2 | 5/4617 (0.1%) | 5 |
| Ventricular fibrillation | 3/4623 (0.1%) | 3 | 15/4617 (0.3%) | 17 |
| Ventricular tachycardia | 15/4623 (0.3%) | 17 | 20/4617 (0.4%) | 23 |
| Congenital, familial and genetic disorders | ||||
| Branchial cyst | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Gastrointestinal angiodysplasia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Glucose-6-phosphate dehydrogenase deficiency | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hydrocele | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Phimosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ear and labyrinth disorders | ||||
| Deafness unilateral | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Vertigo | 5/4623 (0.1%) | 5 | 4/4617 (0.1%) | 4 |
| Vertigo positional | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Endocrine disorders | ||||
| Goitre | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Hyperthyroidism | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Primary hyperaldosteronism | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Primary hypothyroidism | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Eye disorders | ||||
| Amaurosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cataract | 8/4623 (0.2%) | 9 | 4/4617 (0.1%) | 5 |
| Conjunctival haemorrhage | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Corneal oedema | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Diabetic retinopathy | 0/4623 (0%) | 0 | 1/4617 (0%) | 2 |
| Diplopia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Eye haemorrhage | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Glaucoma | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Open angle glaucoma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ophthalmoplegia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Retinal artery occlusion | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Retinal detachment | 0/4623 (0%) | 0 | 2/4617 (0%) | 3 |
| Retinal haemorrhage | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Retinal vein thrombosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Vision blurred | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Vitreous haemorrhage | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Gastrointestinal disorders | ||||
| Abdominal adhesions | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Abdominal hernia | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Abdominal hernia obstructive | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Abdominal pain | 6/4623 (0.1%) | 6 | 6/4617 (0.1%) | 6 |
| Abdominal pain lower | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Abdominal pain upper | 3/4623 (0.1%) | 3 | 4/4617 (0.1%) | 4 |
| Abdominal wall haematoma | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Acute abdomen | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Anal fissure | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Anal fistula | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ascites | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Colitis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Colitis ischaemic | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Colonic polyp | 3/4623 (0.1%) | 3 | 2/4617 (0%) | 2 |
| Constipation | 2/4623 (0%) | 2 | 3/4617 (0.1%) | 3 |
| Dental caries | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Diarrhoea | 1/4623 (0%) | 1 | 4/4617 (0.1%) | 4 |
| Diarrhoea haemorrhagic | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Diverticulum | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Diverticulum intestinal | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Diverticulum intestinal haemorrhagic | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Duodenal polyp | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Duodenal ulcer | 6/4623 (0.1%) | 6 | 4/4617 (0.1%) | 4 |
| Duodenal ulcer haemorrhage | 4/4623 (0.1%) | 4 | 2/4617 (0%) | 2 |
| Duodenitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Dyspepsia | 5/4623 (0.1%) | 5 | 2/4617 (0%) | 2 |
| Dysphagia | 3/4623 (0.1%) | 3 | 4/4617 (0.1%) | 4 |
| Enteritis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Epigastric discomfort | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Erosive duodenitis | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Faecaloma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Femoral hernia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gastric disorder | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gastric haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gastric ulcer | 3/4623 (0.1%) | 3 | 1/4617 (0%) | 1 |
| Gastric ulcer haemorrhage | 3/4623 (0.1%) | 3 | 2/4617 (0%) | 2 |
| Gastric ulcer, obstructive | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Gastritis | 11/4623 (0.2%) | 11 | 4/4617 (0.1%) | 4 |
| Gastritis erosive | 2/4623 (0%) | 2 | 3/4617 (0.1%) | 3 |
| Gastritis haemorrhagic | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Gastrointestinal disorder | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Gastrointestinal haemorrhage | 39/4623 (0.8%) | 39 | 22/4617 (0.5%) | 22 |
| Gastrointestinal inflammation | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gastrointestinal pain | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gastrointestinal ulcer haemorrhage | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Gastrooesophageal reflux disease | 6/4623 (0.1%) | 6 | 3/4617 (0.1%) | 3 |
| Gingival bleeding | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Haematemesis | 6/4623 (0.1%) | 6 | 0/4617 (0%) | 0 |
| Haematochezia | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Haemorrhagic erosive gastritis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Haemorrhoidal haemorrhage | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Haemorrhoids | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hiatus hernia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ileus | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Ileus paralytic | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Impaired gastric emptying | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Inguinal hernia | 2/4623 (0%) | 3 | 6/4617 (0.1%) | 6 |
| Inguinal hernia strangulated | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Inguinal hernia, obstructive | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Intestinal angina | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Intestinal fistula | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Intestinal haemorrhage | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Intestinal ischaemia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Intestinal mass | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Intestinal obstruction | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Irritable bowel syndrome | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Localised intraabdominal fluid collection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Lower gastrointestinal haemorrhage | 8/4623 (0.2%) | 8 | 3/4617 (0.1%) | 3 |
| Mallory-weiss syndrome | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Melaena | 4/4623 (0.1%) | 4 | 1/4617 (0%) | 1 |
| Mesenteric artery embolism | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Nausea | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Oesophageal ulcer | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Oesophageal ulcer haemorrhage | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Oesophagitis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Palatal oedema | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pancreatitis | 1/4623 (0%) | 1 | 5/4617 (0.1%) | 6 |
| Pancreatitis acute | 2/4623 (0%) | 2 | 5/4617 (0.1%) | 5 |
| Pancreatitis chronic | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pancreatitis haemorrhagic | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pancreatitis relapsing | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Peptic ulcer | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Rectal haemorrhage | 11/4623 (0.2%) | 12 | 4/4617 (0.1%) | 4 |
| Retroperitoneal haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Sigmoiditis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Small intestinal obstruction | 3/4623 (0.1%) | 5 | 3/4617 (0.1%) | 4 |
| Small intestinal perforation | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Subileus | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Umbilical hernia | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Upper gastrointestinal haemorrhage | 20/4623 (0.4%) | 21 | 15/4617 (0.3%) | 15 |
| Varices oesophageal | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Vomiting | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| General disorders | ||||
| Adverse drug reaction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Asthenia | 8/4623 (0.2%) | 8 | 3/4617 (0.1%) | 3 |
| Cardiac death | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Chest discomfort | 3/4623 (0.1%) | 3 | 4/4617 (0.1%) | 4 |
| Chest pain | 13/4623 (0.3%) | 14 | 5/4617 (0.1%) | 6 |
| Chills | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Death | 34/4623 (0.7%) | 34 | 40/4617 (0.9%) | 40 |
| Device malfunction | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Euthanasia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Generalised oedema | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Hernia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Impaired healing | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Malaise | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Medical device complication | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Multi-organ failure | 3/4623 (0.1%) | 3 | 5/4617 (0.1%) | 5 |
| Necrosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Non-cardiac chest pain | 66/4623 (1.4%) | 71 | 65/4617 (1.4%) | 78 |
| Oedema peripheral | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pyrexia | 3/4623 (0.1%) | 3 | 3/4617 (0.1%) | 3 |
| Sudden cardiac death | 12/4623 (0.3%) | 12 | 16/4617 (0.3%) | 16 |
| Sudden death | 45/4623 (1%) | 45 | 46/4617 (1%) | 46 |
| Thrombosis in device | 12/4623 (0.3%) | 13 | 23/4617 (0.5%) | 24 |
| Ulcer haemorrhage | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hepatobiliary disorders | ||||
| Bile duct obstruction | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Bile duct stone | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Biliary tract disorder | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cholecystitis | 6/4623 (0.1%) | 6 | 4/4617 (0.1%) | 4 |
| Cholecystitis acute | 9/4623 (0.2%) | 10 | 8/4617 (0.2%) | 9 |
| Cholecystitis chronic | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Cholelithiasis | 4/4623 (0.1%) | 4 | 10/4617 (0.2%) | 10 |
| Cholestasis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Hepatic cirrhosis | 4/4623 (0.1%) | 4 | 0/4617 (0%) | 0 |
| Hepatic failure | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Hepatitis | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Hyperplastic cholecystopathy | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Portal vein thrombosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Immune system disorders | ||||
| Atopy | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Drug hypersensitivity | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Hypersensitivity | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Immunosuppression | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Kidney transplant rejection | 0/4623 (0%) | 0 | 1/4617 (0%) | 2 |
| Infections and infestations | ||||
| Abdominal abscess | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Abdominal sepsis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Abdominal wall abscess | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Abscess limb | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Abscess neck | 0/4623 (0%) | 0 | 1/4617 (0%) | 2 |
| Acute sinusitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Anal abscess | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Appendiceal abscess | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Appendicitis | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Appendicitis perforated | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Bacteraemia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Bronchitis | 11/4623 (0.2%) | 12 | 15/4617 (0.3%) | 15 |
| Bronchitis bacterial | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Bronchopneumonia | 8/4623 (0.2%) | 8 | 8/4617 (0.2%) | 10 |
| Bronchopulmonary aspergillosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Burkholderia cepacia complex infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Burkholderia pseudomallei infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cellulitis | 9/4623 (0.2%) | 9 | 11/4617 (0.2%) | 12 |
| Cholecystitis infective | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cystitis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Cytomegalovirus colitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Device related infection | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Diabetic gangrene | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Diarrhoea infectious | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Disseminated tuberculosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Diverticulitis | 3/4623 (0.1%) | 3 | 1/4617 (0%) | 1 |
| Ear infection | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Eczema infected | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Enterocolitis bacterial | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Erysipelas | 2/4623 (0%) | 2 | 5/4617 (0.1%) | 5 |
| Escherichia urinary tract infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Fungal infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Furuncle | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Gangrene | 4/4623 (0.1%) | 4 | 1/4617 (0%) | 1 |
| Gastroenteritis | 7/4623 (0.2%) | 7 | 7/4617 (0.2%) | 7 |
| Gastroenteritis norovirus | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gastroenteritis viral | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gastrointestinal viral infection | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Groin abscess | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Haematoma infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Helicobacter gastritis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hepatitis b | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Hepatitis c | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Herpes zoster | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Herpes zoster ophthalmic | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Infection | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Infectious peritonitis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Infective exacerbation of chronic obstructive airways disease | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Labyrinthitis | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Lobar pneumonia | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Localised infection | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Lower respiratory tract infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Lower respiratory tract infection viral | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Lung abscess | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Lung infection | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Lymphangitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Malaria | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Mediastinitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Meningitis tuberculous | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Muscle abscess | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Onychomycosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Orchitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Osteomyelitis | 5/4623 (0.1%) | 5 | 4/4617 (0.1%) | 4 |
| Osteomyelitis chronic | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Parametritis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Paronychia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Peridiverticular abscess | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Perirectal abscess | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pneumonia | 74/4623 (1.6%) | 86 | 76/4617 (1.6%) | 79 |
| Pneumonia bacterial | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Pneumonia haemophilus | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pneumonia mycoplasmal | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pneumonia staphylococcal | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Pneumonia viral | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Post procedural infection | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Postoperative wound infection | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Pulmonary tuberculosis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Pyelonephritis | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Pyelonephritis acute | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Pyelonephritis chronic | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pyonephrosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Rectal abscess | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Renal abscess | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Respiratory tract infection | 3/4623 (0.1%) | 3 | 7/4617 (0.2%) | 7 |
| Salmonellosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Scrotal abscess | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Sepsis | 11/4623 (0.2%) | 11 | 12/4617 (0.3%) | 12 |
| Septic shock | 6/4623 (0.1%) | 6 | 8/4617 (0.2%) | 8 |
| Sinusitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Skin infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Staphylococcal bacteraemia | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Staphylococcal infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Staphylococcal sepsis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Subcutaneous abscess | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Tracheobronchitis | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Tuberculosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Upper respiratory tract infection | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Urinary tract infection | 33/4623 (0.7%) | 34 | 19/4617 (0.4%) | 20 |
| Urosepsis | 4/4623 (0.1%) | 4 | 3/4617 (0.1%) | 3 |
| Viral diarrhoea | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Viral infection | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Viral upper respiratory tract infection | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Wound infection | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Injury, poisoning and procedural complications | ||||
| Accidental overdose | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Alcohol poisoning | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Ankle fracture | 2/4623 (0%) | 2 | 4/4617 (0.1%) | 4 |
| Arteriovenous fistula site haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Brain contusion | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Chemical burns of eye | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Concussion | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Confusion postoperative | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Contusion | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Coronary artery restenosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Face injury | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Facial bones fracture | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Fall | 5/4623 (0.1%) | 5 | 1/4617 (0%) | 1 |
| Femoral neck fracture | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Femur fracture | 7/4623 (0.2%) | 7 | 7/4617 (0.2%) | 7 |
| Fibula fracture | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Foot fracture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Gun shot wound | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Haematuria traumatic | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hand fracture | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Head injury | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Hip fracture | 6/4623 (0.1%) | 6 | 6/4617 (0.1%) | 6 |
| Humerus fracture | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| In-stent coronary artery restenosis | 3/4623 (0.1%) | 3 | 7/4617 (0.2%) | 7 |
| Incisional hernia, obstructive | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Joint dislocation | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Limb injury | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Lower limb fracture | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Lumbar vertebral fracture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Multiple drug overdose | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Muscle rupture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Operative haemorrhage | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Overdose | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pelvic fracture | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Periorbital haematoma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Periorbital haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Poisoning | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Post procedural haematoma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Post procedural haemorrhage | 5/4623 (0.1%) | 5 | 4/4617 (0.1%) | 4 |
| Post procedural myocardial infarction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Postoperative fever | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Postoperative thrombosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Postoperative wound complication | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pubis fracture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Rib fracture | 3/4623 (0.1%) | 3 | 2/4617 (0%) | 2 |
| Road traffic accident | 4/4623 (0.1%) | 4 | 1/4617 (0%) | 1 |
| Scapula fracture | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Skeletal injury | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Skull fractured base | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Soft tissue injury | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Spinal column injury | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Spinal compression fracture | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Spinal fracture | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Splenic rupture | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Stab wound | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Sternal fracture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Subcutaneous haematoma | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Subdural haematoma | 7/4623 (0.2%) | 8 | 7/4617 (0.2%) | 7 |
| Subdural haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Tendon rupture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Thermal burn | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Tibia fracture | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Tooth fracture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Toxicity to various agents | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Traumatic haematoma | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Traumatic intracranial haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Vascular graft occlusion | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Vascular pseudoaneurysm | 3/4623 (0.1%) | 3 | 2/4617 (0%) | 2 |
| Weaning failure | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Wound | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Wound dehiscence | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Wound haemorrhage | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Wound secretion | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Investigations | ||||
| Acinetobacter test positive | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Alanine aminotransferase increased | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Angiogram | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Aspartate aminotransferase increased | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Blood glucose fluctuation | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Blood glucose increased | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Blood pressure increased | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Catheterisation cardiac | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Coagulation time prolonged | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ejection fraction decreased | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Electrocardiogram qt prolonged | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Electrocardiogram st segment elevation | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Haematocrit decreased | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Haemoglobin decreased | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Hepatic enzyme increased | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Occult blood | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Prostatic specific antigen increased | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Metabolism and nutrition disorders | ||||
| Acidosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cachexia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Dehydration | 4/4623 (0.1%) | 4 | 5/4617 (0.1%) | 5 |
| Diabetes mellitus | 13/4623 (0.3%) | 13 | 9/4617 (0.2%) | 9 |
| Diabetes mellitus inadequate control | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Diabetic foot | 5/4623 (0.1%) | 5 | 3/4617 (0.1%) | 3 |
| Diabetic ketoacidosis | 3/4623 (0.1%) | 4 | 5/4617 (0.1%) | 5 |
| Electrolyte imbalance | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Failure to thrive | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Fluid overload | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Gout | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Hyperglycaemia | 6/4623 (0.1%) | 7 | 5/4617 (0.1%) | 6 |
| Hyperkalaemia | 3/4623 (0.1%) | 3 | 8/4617 (0.2%) | 8 |
| Hypoglycaemia | 10/4623 (0.2%) | 11 | 13/4617 (0.3%) | 14 |
| Hypokalaemia | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Hyponatraemia | 6/4623 (0.1%) | 6 | 4/4617 (0.1%) | 4 |
| Hypovolaemia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Metabolic acidosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Obesity | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Shock hypoglycaemic | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Type 2 diabetes mellitus | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Arthritis | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Back pain | 5/4623 (0.1%) | 5 | 5/4617 (0.1%) | 5 |
| Bursitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cervical spinal stenosis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Costochondritis | 2/4623 (0%) | 2 | 4/4617 (0.1%) | 4 |
| Dupuytren's contracture | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Gouty arthritis | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Haemarthrosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Intervertebral disc degeneration | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Intervertebral disc disorder | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Intervertebral disc protrusion | 5/4623 (0.1%) | 5 | 2/4617 (0%) | 3 |
| Joint effusion | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Musculoskeletal chest pain | 5/4623 (0.1%) | 5 | 5/4617 (0.1%) | 5 |
| Musculoskeletal pain | 5/4623 (0.1%) | 5 | 1/4617 (0%) | 1 |
| Myalgia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Myopathy | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Osteoarthritis | 6/4623 (0.1%) | 6 | 11/4617 (0.2%) | 11 |
| Osteochondritis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Osteoporosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pain in extremity | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Periarthritis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Psoriatic arthropathy | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Rhabdomyolysis | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Rheumatoid arthritis | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Spinal column stenosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Spinal osteoarthritis | 1/4623 (0%) | 1 | 4/4617 (0.1%) | 4 |
| Spondylitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Synovial cyst | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Synovitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Tenosynovitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Vertebral foraminal stenosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||
| Benign laryngeal neoplasm | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Benign ovarian tumour | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Benign renal neoplasm | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Benign small intestinal neoplasm | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Colon adenoma | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Lipoma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Phaeochromocytoma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Prostatic adenoma | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Uterine leiomyoma | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Nervous system disorders | ||||
| Aphasia | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Autonomic neuropathy | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Basal ganglia haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Brain oedema | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Brain stem stroke | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Carotid arteriosclerosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Carotid artery aneurysm | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Carotid artery disease | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Carotid artery occlusion | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Carotid artery stenosis | 4/4623 (0.1%) | 4 | 6/4617 (0.1%) | 6 |
| Carotid sinus syndrome | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cerebellar infarction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cerebral haematoma | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Cerebral haemorrhage | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cerebral hypoperfusion | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cerebral infarction | 5/4623 (0.1%) | 5 | 3/4617 (0.1%) | 3 |
| Cerebrovascular accident | 33/4623 (0.7%) | 34 | 19/4617 (0.4%) | 19 |
| Cervical root pain | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cervicobrachial syndrome | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Cluster headache | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Coma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Convulsion | 3/4623 (0.1%) | 3 | 2/4617 (0%) | 2 |
| Diabetic neuropathy | 0/4623 (0%) | 0 | 3/4617 (0.1%) | 3 |
| Dizziness | 5/4623 (0.1%) | 5 | 5/4617 (0.1%) | 5 |
| Encephalopathy | 2/4623 (0%) | 3 | 2/4617 (0%) | 2 |
| Epilepsy | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Grand mal convulsion | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Haemorrhage intracranial | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Haemorrhagic stroke | 3/4623 (0.1%) | 3 | 5/4617 (0.1%) | 5 |
| Headache | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Hemiparesis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hydrocephalus | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Hypoaesthesia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hypoxic-ischaemic encephalopathy | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Iiird nerve paresis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Intracranial aneurysm | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Intracranial hypotension | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ischaemic cerebral infarction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Ischaemic stroke | 24/4623 (0.5%) | 24 | 30/4617 (0.6%) | 31 |
| Lacunar infarction | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Metabolic encephalopathy | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Migraine | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Neuralgia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Normal pressure hydrocephalus | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Occipital neuralgia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Paraesthesia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Partial seizures | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pneumocephalus | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Polyneuropathy | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Post-traumatic epilepsy | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Presyncope | 5/4623 (0.1%) | 5 | 9/4617 (0.2%) | 9 |
| Radiculitis lumbosacral | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Sciatica | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Spinal cord herniation | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Spinal cord infarction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Subarachnoid haemorrhage | 4/4623 (0.1%) | 4 | 2/4617 (0%) | 2 |
| Syncope | 28/4623 (0.6%) | 30 | 27/4617 (0.6%) | 29 |
| Transient ischaemic attack | 9/4623 (0.2%) | 9 | 11/4617 (0.2%) | 12 |
| Tremor | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Vertebrobasilar insufficiency | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Viith nerve paralysis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Psychiatric disorders | ||||
| Abnormal behaviour | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Affective disorder | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Agitation | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Alcohol abuse | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Anxiety | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Anxiety disorder | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Bipolar disorder | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Confusional state | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Delirium | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Depression | 7/4623 (0.2%) | 7 | 2/4617 (0%) | 2 |
| Mental disorder | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Mental status changes | 4/4623 (0.1%) | 4 | 3/4617 (0.1%) | 3 |
| Panic attack | 1/4623 (0%) | 1 | 1/4617 (0%) | 2 |
| Psychosomatic disease | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Psychotic disorder due to a general medical condition | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Suicidal ideation | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Suicide attempt | 2/4623 (0%) | 2 | 2/4617 (0%) | 2 |
| Renal and urinary disorders | ||||
| Acute prerenal failure | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Bladder outlet obstruction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Calculus bladder | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Calculus ureteric | 4/4623 (0.1%) | 4 | 4/4617 (0.1%) | 4 |
| Calculus urinary | 3/4623 (0.1%) | 3 | 0/4617 (0%) | 0 |
| Diabetic nephropathy | 3/4623 (0.1%) | 3 | 3/4617 (0.1%) | 3 |
| Haematuria | 10/4623 (0.2%) | 10 | 10/4617 (0.2%) | 11 |
| Haemorrhage urinary tract | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hydronephrosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Mesangioproliferative glomerulonephritis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Nephrolithiasis | 1/4623 (0%) | 2 | 3/4617 (0.1%) | 3 |
| Nephropathy toxic | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Nephrotic syndrome | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pyelocaliectasis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Renal artery stenosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Renal colic | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Renal failure | 12/4623 (0.3%) | 12 | 7/4617 (0.2%) | 7 |
| Renal failure acute | 21/4623 (0.5%) | 22 | 20/4617 (0.4%) | 21 |
| Renal failure chronic | 9/4623 (0.2%) | 9 | 9/4617 (0.2%) | 9 |
| Renal impairment | 0/4623 (0%) | 0 | 3/4617 (0.1%) | 3 |
| Renal injury | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Ureteric stenosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Urethral stenosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Urinary hesitation | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Urinary retention | 1/4623 (0%) | 1 | 2/4617 (0%) | 2 |
| Urinary tract inflammation | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Reproductive system and breast disorders | ||||
| Benign prostatic hyperplasia | 4/4623 (0.1%) | 4 | 3/4617 (0.1%) | 3 |
| Breast haematoma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cervical dysplasia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Endometrial hyperplasia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Epididymitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Menorrhagia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Ovarian cyst | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pelvic haematoma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Prostatitis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Sexual dysfunction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Uterine prolapse | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Vaginal haemorrhage | 3/4623 (0.1%) | 3 | 2/4617 (0%) | 3 |
| Vaginal prolapse | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Acute pulmonary oedema | 14/4623 (0.3%) | 18 | 23/4617 (0.5%) | 27 |
| Acute respiratory distress syndrome | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Acute respiratory failure | 7/4623 (0.2%) | 8 | 11/4617 (0.2%) | 13 |
| Alveolitis allergic | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Asthma | 7/4623 (0.2%) | 7 | 3/4617 (0.1%) | 3 |
| Bronchiectasis | 1/4623 (0%) | 1 | 1/4617 (0%) | 3 |
| Bronchitis chronic | 3/4623 (0.1%) | 3 | 2/4617 (0%) | 2 |
| Bronchospasm | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Choking | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Chronic obstructive pulmonary disease | 26/4623 (0.6%) | 26 | 31/4617 (0.7%) | 32 |
| Cough | 1/4623 (0%) | 1 | 1/4617 (0%) | 2 |
| Dyspnoea | 10/4623 (0.2%) | 12 | 9/4617 (0.2%) | 9 |
| Dyspnoea exertional | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Emphysema | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Epistaxis | 11/4623 (0.2%) | 11 | 9/4617 (0.2%) | 9 |
| Haemoptysis | 4/4623 (0.1%) | 4 | 2/4617 (0%) | 2 |
| Haemothorax | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hyperventilation | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Hypoxia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Interstitial lung disease | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Lung disorder | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Nasal obstruction | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Nasal polyps | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Nocturnal dyspnoea | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Obstructive airways disorder | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Occupational asthma | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Organising pneumonia | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pleural effusion | 3/4623 (0.1%) | 3 | 8/4617 (0.2%) | 8 |
| Pleuritic pain | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Pneumonia aspiration | 3/4623 (0.1%) | 3 | 0/4617 (0%) | 0 |
| Pneumonitis | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Pneumothorax | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pulmonary congestion | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Pulmonary embolism | 12/4623 (0.3%) | 12 | 11/4617 (0.2%) | 11 |
| Pulmonary fibrosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pulmonary haemorrhage | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Pulmonary hypertension | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Pulmonary infarction | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Pulmonary oedema | 15/4623 (0.3%) | 15 | 16/4617 (0.3%) | 19 |
| Respiratory arrest | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Respiratory distress | 0/4623 (0%) | 0 | 4/4617 (0.1%) | 4 |
| Respiratory failure | 8/4623 (0.2%) | 8 | 10/4617 (0.2%) | 10 |
| Tonsillar haemorrhage | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Tracheomalacia | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Skin and subcutaneous tissue disorders | ||||
| Angioedema | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Dermatitis allergic | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Diabetic ulcer | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Dry gangrene | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Ecchymosis | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Skin ulcer | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Stasis dermatitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Social circumstances | ||||
| Activities of daily living impaired | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Elderly | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Surgical and medical procedures | ||||
| Angioplasty | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Arterial repair | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cardiac pacemaker battery replacement | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Cardiac pacemaker insertion | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Cataract operation | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Coronary arterial stent insertion | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Coronary artery bypass | 7/4623 (0.2%) | 7 | 1/4617 (0%) | 1 |
| Coronary revascularisation | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hernia repair | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Hospitalisation | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Implantable defibrillator insertion | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Implantable defibrillator replacement | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Knee operation | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Medical device implantation | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Percutaneous coronary intervention | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Rehabilitation therapy | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Umbilical hernia repair | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Vascular disorders | ||||
| Accelerated hypertension | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Aortic aneurysm | 4/4623 (0.1%) | 4 | 3/4617 (0.1%) | 3 |
| Aortic aneurysm rupture | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Aortic stenosis | 3/4623 (0.1%) | 3 | 3/4617 (0.1%) | 3 |
| Arterial disorder | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Arterial insufficiency | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Arterial thrombosis limb | 1/4623 (0%) | 2 | 3/4617 (0.1%) | 3 |
| Arteriosclerosis | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Bleeding varicose vein | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Deep vein thrombosis | 3/4623 (0.1%) | 3 | 8/4617 (0.2%) | 8 |
| Diabetic vascular disorder | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Distributive shock | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Essential hypertension | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Femoral arterial stenosis | 2/4623 (0%) | 2 | 0/4617 (0%) | 0 |
| Haematoma | 5/4623 (0.1%) | 5 | 4/4617 (0.1%) | 4 |
| Haemorrhage | 2/4623 (0%) | 2 | 1/4617 (0%) | 1 |
| Hypertension | 29/4623 (0.6%) | 29 | 24/4617 (0.5%) | 24 |
| Hypertensive crisis | 13/4623 (0.3%) | 14 | 11/4617 (0.2%) | 12 |
| Hypotension | 8/4623 (0.2%) | 8 | 9/4617 (0.2%) | 10 |
| Hypovolaemic shock | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Iliac artery occlusion | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Iliac artery thrombosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Intermittent claudication | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Lymphoedema | 1/4623 (0%) | 1 | 0/4617 (0%) | 0 |
| Orthostatic hypotension | 3/4623 (0.1%) | 3 | 3/4617 (0.1%) | 4 |
| Peripheral arterial occlusive disease | 13/4623 (0.3%) | 13 | 15/4617 (0.3%) | 15 |
| Peripheral artery aneurysm | 1/4623 (0%) | 4 | 0/4617 (0%) | 0 |
| Peripheral embolism | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Peripheral ischaemia | 1/4623 (0%) | 1 | 2/4617 (0%) | 3 |
| Peripheral vascular disorder | 4/4623 (0.1%) | 4 | 6/4617 (0.1%) | 6 |
| Phlebitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Shock | 0/4623 (0%) | 0 | 2/4617 (0%) | 2 |
| Subclavian vein thrombosis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Temporal arteritis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Thrombophlebitis | 1/4623 (0%) | 1 | 1/4617 (0%) | 1 |
| Thrombophlebitis superficial | 1/4623 (0%) | 1 | 3/4617 (0.1%) | 3 |
| Varicophlebitis | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Varicose ulceration | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Varicose vein | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
| Venous insufficiency | 0/4623 (0%) | 0 | 1/4617 (0%) | 1 |
Other (Not Including Serious) Adverse Events |
||||
| Prasugrel | Clopidogrel | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 2581/4623 (55.8%) | 2494/4617 (54%) | ||
| Blood and lymphatic system disorders | ||||
| Anaemia | 103/4623 (2.2%) | 106 | 75/4617 (1.6%) | 76 |
| Cardiac disorders | ||||
| Angina pectoris | 213/4623 (4.6%) | 267 | 250/4617 (5.4%) | 320 |
| Atrial fibrillation | 93/4623 (2%) | 102 | 110/4617 (2.4%) | 116 |
| Gastrointestinal disorders | ||||
| Abdominal pain upper | 41/4623 (0.9%) | 44 | 49/4617 (1.1%) | 51 |
| Constipation | 71/4623 (1.5%) | 76 | 81/4617 (1.8%) | 83 |
| Diarrhoea | 94/4623 (2%) | 99 | 87/4617 (1.9%) | 92 |
| Dyspepsia | 51/4623 (1.1%) | 51 | 51/4617 (1.1%) | 52 |
| Gastritis | 50/4623 (1.1%) | 52 | 60/4617 (1.3%) | 60 |
| Gastrooesophageal reflux disease | 46/4623 (1%) | 47 | 48/4617 (1%) | 49 |
| Nausea | 74/4623 (1.6%) | 78 | 80/4617 (1.7%) | 83 |
| General disorders | ||||
| Asthenia | 57/4623 (1.2%) | 59 | 45/4617 (1%) | 47 |
| Chest pain | 37/4623 (0.8%) | 45 | 48/4617 (1%) | 68 |
| Fatigue | 82/4623 (1.8%) | 84 | 70/4617 (1.5%) | 75 |
| Non-cardiac chest pain | 108/4623 (2.3%) | 125 | 120/4617 (2.6%) | 149 |
| Oedema peripheral | 90/4623 (1.9%) | 94 | 123/4617 (2.7%) | 132 |
| Infections and infestations | ||||
| Bronchitis | 87/4623 (1.9%) | 94 | 84/4617 (1.8%) | 90 |
| Nasopharyngitis | 68/4623 (1.5%) | 74 | 74/4617 (1.6%) | 91 |
| Pneumonia | 39/4623 (0.8%) | 42 | 49/4617 (1.1%) | 51 |
| Upper respiratory tract infection | 57/4623 (1.2%) | 63 | 75/4617 (1.6%) | 82 |
| Urinary tract infection | 101/4623 (2.2%) | 116 | 101/4617 (2.2%) | 112 |
| Injury, poisoning and procedural complications | ||||
| Contusion | 175/4623 (3.8%) | 229 | 107/4617 (2.3%) | 165 |
| Metabolism and nutrition disorders | ||||
| Diabetes mellitus | 64/4623 (1.4%) | 65 | 79/4617 (1.7%) | 79 |
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 64/4623 (1.4%) | 71 | 63/4617 (1.4%) | 68 |
| Back pain | 85/4623 (1.8%) | 85 | 90/4617 (1.9%) | 96 |
| Pain in extremity | 72/4623 (1.6%) | 76 | 69/4617 (1.5%) | 70 |
| Nervous system disorders | ||||
| Dizziness | 121/4623 (2.6%) | 131 | 142/4617 (3.1%) | 158 |
| Headache | 109/4623 (2.4%) | 115 | 116/4617 (2.5%) | 127 |
| Psychiatric disorders | ||||
| Anxiety | 63/4623 (1.4%) | 63 | 61/4617 (1.3%) | 63 |
| Depression | 60/4623 (1.3%) | 61 | 66/4617 (1.4%) | 67 |
| Insomnia | 53/4623 (1.1%) | 53 | 67/4617 (1.5%) | 67 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Cough | 140/4623 (3%) | 142 | 134/4617 (2.9%) | 146 |
| Dyspnoea | 98/4623 (2.1%) | 110 | 116/4617 (2.5%) | 120 |
| Dyspnoea exertional | 34/4623 (0.7%) | 35 | 49/4617 (1.1%) | 50 |
| Epistaxis | 184/4623 (4%) | 265 | 112/4617 (2.4%) | 149 |
| Skin and subcutaneous tissue disorders | ||||
| Ecchymosis | 123/4623 (2.7%) | 166 | 65/4617 (1.4%) | 78 |
| Vascular disorders | ||||
| Haematoma | 116/4623 (2.5%) | 141 | 63/4617 (1.4%) | 78 |
| Hypertension | 161/4623 (3.5%) | 162 | 153/4617 (3.3%) | 156 |
| Hypotension | 48/4623 (1%) | 50 | 54/4617 (1.2%) | 55 |
Limitations/Caveats
[Not Specified]
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Chief Medical Officer |
|---|---|
| Organization | Eli Lilly and Company |
| Phone | 800-545-5979 |
Responsible Party:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00699998
Other Study ID Numbers:
- 11058
- H7T-MC-TABY(b)
First Posted:
Jun 18, 2008
Last Update Posted:
May 7, 2013
Last Verified:
Mar 1, 2013